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Abstract 
This commentary addresses data quality in equilibrium solubility measurement in aqueous solution. Broadly 
discussed is the “gold standard” shake-flask (SF) method used to measure equilibrium solubility of ionizable 
drug-like molecules as a function of pH. Many factors affecting the quality of the measurement are recognized. 
Case studies illustrating the analysis of both solution and solid state aspects of solubility measurement are 
presented. Coverage includes drug aggregation in solution (sub-micellar, micellar, complexation), use of mass 
spectrometry to assess aggregation in saturated solutions, solid state characterization (salts, polymorphs, 
cocrystals, polymorph creation by potentiometric method), solubility type (water, buffer, intrinsic), 
temperature, ionic strength, pH measurement, buffer issues, critical knowledge of the pKa, equilibration time 
(stirring and sedimentation), separating solid from saturated solution, solution handling and adsorption to 
untreated surfaces, solubility units, and tabulation/graphic presentation of reported data. The goal is to 
present cohesive recommendations that could lead to better assay design, to result in improved quality of 
measurements, and to impart a deeper understanding of the underlying solution chemistry in suspensions of 
drug solids. 
Keywords 
shake-flask solubility; intrinsic solubility; water solubility; buffer solubility; thermodynamic solubility; Bjerrum 
curve; CheqSol; Potentiometric Cycling for Polymorph Creation; Henderson-Hasselbalch equation; aggregates; 
oligomers; micelles; hydrates; salts; polymorphs; cocrystals.  
 
Introduction 
Many investigational compounds in pharmaceutical development are practically insoluble solids consisting 
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of ionizable molecules. Interpreting their solution properties in the course of measuring solubility – as a 
function of pH – can be problematic. Although there are a multitude of published methods, today’s druglike 
molecules can pose special challenges, perhaps not adequately addressed in practice. The published literature 
is replete with incomplete/ambiguous and potentially misleading examples of solubility reports, frequently 
documented inconsistently. The solubility methodology appears to be in need of a timely tune up. 
This commentary discusses ways to improve the measurement of thermodynamic solubility of druglike 
substances in aqueous media. (Topics such as solubility in bio-relevant media, kinetic solubility, and solubility 
of amorphous and of liquid-liquid phase separated (LLPS) solids are outside of its scope.) It is relatively scarce 
to find many high-quality solubility measurements that adequately cover the chemical space of drugs and 
research compounds. Measuring such data is expensive and analytical-resource consuming. Even with great 
expense, quality is not ensured when results are determined from under-designed assays. The “Solubility 
Challenge” from Llinàs et al. [1] and Hopfinger et al. [2] has spurred fresh discussion about data quality in 
solubility measurement in pharmaceutical research. Concomitantly, Baka et al. [3] examined the classical 
saturation shake-flask method, to assess which experimental conditions significantly affect the measured 
equilibrium solubility. More recently, solubility data quality has been reviewed by Avdeef [4]. 
Optimal experimental design to measure the aqueous equilibrium solubility of an ionizable substance 
requires a number of critical considerations. Briefly, the aqueous medium to which the substance is added 
ideally contains a buffer to help control the pH. To this medium, the substance may be added in a number of 
ways: (a) as a highly supersaturated aqueous solution, (b) as a saturated hot solution, (c) as a concentrated 
solution in a water-miscible organic solvent, or (d) as a solid – which may or may not be in a 
thermodynamically stable form. The first three approaches are precipitation routes, while the fourth involves 
dissolution. The latter process is most commonly used, best understood, and is the backbone of the 
commentary here. 
Solubility reactions, being heterogeneous, are often slow to reach equilibrium, especially in the case of low-
soluble substances. With sufficient added solid and enough time, chemical equilibrium is expected, where the 
substance in its stable crystalline form is in dynamic equilibrium with its solution form. As the dissolution 
proceeds, the solid phase can re-precipitate as another form with another structure (polymorphic transitions) 
and even another composition (formation of crystal solvates, salts, or loss of solvate from the starting solid). 
Dissolution of multi-component solids (salts – formed by cations and anions, or cocrystals – formed by neutral 
molecules, a drug and another molecule, termed a “coformer”, which are often strongly hydrogen-bonded) 
adds complexity, since on their dissolution, re-crystallization of some components can start, depending on the 
solution conditions. The values of the solubility measured at different time points will therefore correspond to 
different solid phases, not necessarily the one initially introduced into solution. Sometimes a long equilibration 
time is needed to settle to the most stable crystalline form. In solution, the substance may undergo ionization, 
self-aggregation (forming water-soluble dimers, trimers, etc., or micelles in the case of amphiphilic 
substances), or complexation with some of the buffer components. In some cases, solids dissolve as clusters of 
molecules, which can be preserved for some time before being broken apart by the solvent. At true dynamic 
equilibrium, the forward (dissolution) and reverse (precipitation) reaction rates are equal to one another. In 
this dynamically equilibrated saturated solution, the concentration of the drug substance (summed over all of 
its dissolved forms) is the solubility. Both phases of the solubility process are important to consider, as 
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measured solubility depends both on the solid and the solution forms. Since the solubility is temperature 
dependent, the temperature needs to be controlled. For ionizable substances, solubility depends on pH, so the 
final (equilibrium) pH of the saturated solution, pHsat, needs to be measured directly.  
Methods of characterizing the solid state (powder X-ray diffraction, differential scanning calorimetry, FT-IR 
reflectance/Raman spectra of slurries, elemental analysis, etc.) are well established. This is an important 
consideration with actionable consequences, since patents may be issued to cover particular solid state forms 
of a marketed drug substance. 
However, characterizations of the solution state of ionizable substances of sparingly-soluble or amphiphilic 
substances that are surface active are far less well explored. This is especially true of ionizable substances in 
saturated solutions above their critical micelle concentration (CMC), with the assay temperature being above 
the Krafft point [5]. Under such circumstances, crystalline solids of the substance are effectively in equilibrium 
with micelles (or sub-micellar aggregates), in some cases leading to the transient formation of oils if the 
melting point of the neutral form of the substance is not far above the assay temperature. Such solutions can 
be very sensitive to changes in pH and/or temperature, as well as by the presence of background salts and 
other excipients [6].  
This commentary is the outgrowth of discussions held during the “Thermodynamic Solubility Measurement 
of Practically Insoluble Ionizable Drugs – Case Studies & Suggested Method Improvements” session at the 4th 
World Conference on Physico Chemical Methods in Drug Discovery and Development (PCMDDD-4, 
http://www.iapchem.org/page.php?page_id=56), held on Red Island, Croatia, 21-24 September 2015. The 
session focused on discussing the best practices for the saturation shake-flask measurement of solubility as a 
function of pH (the “gold standard” methodology), along with promising potentiometric methods, and 
attempted to reach a consensus about the best approaches for studying sparingly soluble drug substances. A 
questionnaire was prepared and distributed to the attendees. The responses received from several of the 
participants are summarized in Appendix D.  
Several excellent books and reviews serve as background material for the commentary covering the 
solubility of druglike molecules: general coverage of solubility [7-10]; salt formation/selection [11-16]; 
polymorphism [17-20]; analysis of saturated solution speciation [21-27]; dissolution/solubility of cocrystals 
[28-37]; anhydrous forms versus hydrates [16, 38, 39].  
Case Studies  
The commentary begins with several selected case studies of molecules which illustrate appreciable 
challenges encountered in the measurement of solubility. Figure 1 shows four examples of drugs which reveal 
relatively simple logS-pH profiles, which can be more or less predicted by the Henderson-Hasselbalch (HH) 
equation [27, 40, 41]. Figure 2 shows three examples of molecules with logS-pH profiles that are consistent 
with the presence of anionic or uncharged self-associated aggregates, and one case consistent with drug-
buffer interaction. Figure 3 illustrates the logS-pH profiles of haloperidol resulting from different salt 
precipitations, illustrating some degree of supersaturation for two cases near the Gibbs pKa [42, 43] in the pH 
4.1-4.9 interval and the possible formation of uncharged aggregates for pH>8. Figures 4 and 5 ratchet up the 
complexity of logS-pH profiles of surface-active molecules which precipitate both as salts and as uncharged species. 
The examples were selected to show that care needs to be exercised in interpreting the shapes of the solubility-pH 
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profiles [21-25] and that assays need to be optimized to enhance the confidence in the interpretations of the data.  
 
  
  
Figure 1. Four examples of drugs which reveal relatively simple logS-pH profiles, which can be more or less 
predicted by the Henderson-Hasselbalch equation. 
The following logS-pH curve notations are used (except Figures 4b and 5b):  
 The dashed curves refer to the profiles calculated from the simple HH equation (not corrected for ionic 
strength or dilution effects) 
 The solid curves are calculated using the refined constants from fitting the measured logS-pH data (filled 
circles) to the proposed equilibrium model, using the pDISOL-X program (in-ADME Research; 
www.in-adme.com/pdisol_x.html)  
 The dotted curves indicate regions of pH of subsaturation, where the substances are dissolved 
 S0 refers to the intrinsic solubility of the uncharged form of the substance 
 pKsp refers to the negative log of the salt (or cocrystal, as in later sections) solubility product 
 The reference and average ionic strengths are indicated as Iref and Iavg, respectively. The former values 
correspond to the pKa determination conditions. Corrections are made for changes in the ionic strength 
in the solubility assays, as described by Völgyi et al. [22] and Wang et al. [44] 
 The jH coefficients (Figure 3b,c,d) refer to estimated pH electrode junction potential factors [45] in very 
acidic solutions (pH < 1), as detailed in Appendix C. 
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Atenolol 
Figure 1a shows the logS-pH profile of atenolol [46]. Since the weak base is relatively soluble, it takes a 
3.8 M atenolol solution (1 g of the free base added to 1 mL of 50 mM phosphate buffer) to span the 
concentration range shown in the figure. The ionic strength rises from 0.24 to 0.83 M as pH is lowered from 
9.5 to 8.5 using 1 M HCl. Such pH adjustment is accompanied by a very large dilution effect. This requires that 
the pH electrode used be well-calibrated. Since the accurate pKa of atenolol is known, the fit can be further 
improved over what is shown, by assuming the presence of a neutral aggregate species, (Case 1b in [27]); the 
standard deviation drops from 0.047 to 0.015 log unit. The intrinsic solubility is slightly lessened from 14.1 to 
11.0 mg/mL. The performance of the pH electrode is quite important in this case study.  
Atorvastatin 
Figure 1b shows the logS-pH profile of atorvastatin added as the calcium salt [47]. This example illustrates 
the need to know the pKa accurately. The value of 4.37 at 37 
o
C was predicted [26] from the measured value at 
25 
o
C [48]. If 4.37 is the correct value, then the small parallel displacement of the solubility values in the pH 4-5 
region to lower pH is consistent with the presence of half-ionized aggregates, [AH.A
–
]n, (Case 3a in [27]). On 
the other hand, it could be assumed that the reported pKa is inaccurate, and that no aggregates form in the pH 
4-5 region. Then, the ionization constant determined by pDISOL-X would be 3.94 ± 0.09, using the logS-pH 
data, based on methods popularized in older literature [49, 50]. Such a big difference (0.43 log unit) seems 
unrealistic, so the case for aggregation cannot be easily dismissed. 
For the aggregate model in the figure, as the pH is increased from 1 to 5, the only solid present in the 
suspension is the free acid, HA. As pH increases to 5, the free [Ca
2+
] remains constant at 1.78 mM, as [A
–
] 
increases. When pH 5 is reached, the salt solubility product is exceeded and the calcium salt of the drug, 
CaA2(s), begins to co-precipitate with HA(s) until pH 5.5. Between pH 5.0 and 5.5, the calcium concentration 
decreases by the same extent as that of atorvastatin anion increases, but the product [Ca2+][A–]2 remains 
constant. This is the pH interval containing two different solids. Above pH 5.5 (the point of maximum 
solubility), all HA(s) dissolves, as [Ca
2+
] levels off at 0.09 mM, and only the calcium salt is predicted to 
precipitate, as the above product of concentrations remains constant. It may be surprising that as an added 
calcium salt, atorvastatin does not have a distinct Gibbs pKa [42, 43], but rather shows co-precipitation over a 
0.5 pH interval. Had the precipitate been between the drug and sodium ions, there would have been a distinct 
pKa
Gibbs. The system is complex and several models can be proposed to rationalize the logS-pH profile. As can 
be seen, the independently-determined pKa is critical to the analysis of the data. It would have been important 
to isolate and characterize the solids, at least by elemental analysis, if not by comparison to PXRD of 
demonstrated crystalline solids of known stoichiometry. Sufficiently sensitive computations tools are needed 
to fully interpret such complicated systems. 
Amifloxacin 
Figure 1c shows the logS-pH profile of amifloxacin, an ampholyte which forms a hydrochloride salt below 
pH 5 [51]. The region of maximum solubility near pH 5 showed supersaturation effects, especially at 
equilibration times < 24 h. The data in the figure are based on 48 h equilibration time. The unfilled circle was 
assigned zero weight in the refinement, since no equilibrium model could be found to fold the point into the 
curve represented by the other points. Also, the region between pH 5 and 6 indicated the presence of a small 
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amount of Case 2b-type in [27] cationic dimeric aggregate. This example illustrates the time dependence of 
the measured solubility. 
Ampicillin and Ampicillin Trihydrate 
Figure 1d shows the logS-pH profiles of two forms of ampicillin: anhydrous (unfilled circles) and trihydrate 
(filled circles) [52]. It is noteworthy that the equilibration times were 2 h in both cases. Had longer dissolution 
times been used, the more soluble anhydrous form would likely have converted into the trihydrate. Many 
anhydrous forms of drugs are near 2-fold higher in solubility than their hydrate counter parts [4, 18]. The two 
profiles are well-described by the simple HH equation. 
Cefadroxil 
Figure 2a shows the logS-pH profile of cefadroxil, which illustrates two complicating aspect of solubility 
equilibria [53]. The study considered many different buffers: acetate, ammonium, borate, citrate, formate, 
lactate, and phosphate. The analysis of the data here excluded the measurements in citrate (unfilled squares) 
  
 
Figure 2. Shown are three examples of molecules with logS-pH profiles which are consistent with the presence of 
anionic or uncharged self-associated aggregates, and one case consistent with drug-buffer interaction.   
and lactate (unfilled circles) buffers, since their solubility in acidic solutions tended to deviate from the curve 
composed of all the other buffer measurements. The elevated solubility of the lactate and citrate cases 
suggested that complexes might have formed between the buffer anions and the positively-charged cefadroxil, 
complicating the solution chemistry. The analysis of the non-complicating buffer data yielded the solid curve in 
the figure. Evidently, the data above pH 6 cannot be predicted by the simple HH equation. Using pDISOL-X, the 
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data were best fit by assuming the presence of anionic monomers and trimers (Case 2a in [27]) of cefadroxil. 
Shoghi et al. [53] proceeded to analyze the solutions between pH 6 and 7 using low ionization energy ESI-Q-
TOF-MS/MS and found direct evidence for the presence of monomers, dimers and trimers in saturated 
solution. This example illustrates the importance of corroborating proposed solution-phase equilibrium 
models by independent methods. 
Diprenorphine 
Figure 2b shows the solubility profile of diprenorphine hydrochloride, XH2.Cl, in the modified Sørensen’s 
buffer: 0.15 M NaH2PO4 adjusted with 14.85 M H3PO4 or 0.5 M NaOH [22]. The two pKa values of diprenorphine 
were carefully determined in the study by Völgyi et al. [22]. For pH>pKa
Gibbs
 5.07, the precipitate is the 
uncharged ordinary ampholyte, showing the characteristic parabolic shape. At pH below the Gibbs pKa, either 
the chloride or the phosphate salt precipitates (or possibly both). Based on the reported solubility data, it is 
not definitively certain which form precipitates. More data would be needed at very low pH. Alternatively, the 
salts could have been isolated and characterized. The flat shape of the curve pH 2-5 is most consistent with 
chloride precipitate. A phosphate precipitate would be expected to show an upward curvature near the 
pKaGibbs. At pH>9, the logS-pH curve shows a shift to lower pH, compared that what would be predicted from 
the simple HH equation. The consistent interpretation of the shift is that a water-soluble mixed-charge anionic 
dimer forms, with the basic stoichiometry XHX
–
 (Case 3a in [27]).  
Ametryne 
Figure 2c shows the solubility profile of ametryne [54], a weak base that appears to show free-base 
aggregation (Case 1b in [27]). As reported, there was no indication of supersaturation effects at the 24 h 
equilibration. The pKa was spectrophotometrically determined [55]. Several other derivatives (but not all) 
studied by Ward and Weber [54] showed the characteristic Case 1b logS-pH pattern. If the free-base 
aggregation model were not invoked, then the refined pKa would be 3.14 ± 0.08, almost a log unit lower than 
the measured value. This example illustrates the need for independently measuring the pKa, under conditions 
free of effects of aggregation and precipitation. Also, a mass spectrophotometric analysis of the slurry in 
neutral solution would have been corroboratively valuable.  
Haloperidol 
The salt solubility of haloperidol described by Li et al. [56, 57] raises several interesting points in assay 
design and data interpretation. Figure 3 illustrates the pH-dependent formation of three crystalline salts of 
haloperidol: hydrochloride, mesylate, and phosphate.   
In the first three frames of the figure, HCl or NaOH were used to adjust the pH of haloperidol, either 
introduced as a free base (Figure 3a) or as a hydrochloride (Figure 3b). Within the bounds of experimental 
errors, the results are largely the same. The data in the hydrochloride case (Figure 3b) above pH 8 indicate a 
non-HH effect, which can be due to three situations: (i) formation of uncharged aggregates (Case 1b in [27]), or 
(ii) 24 h time not being adequate to reach full equilibration, or (iii) the formation of an oil phase (liquid-liquid 
phase separation, LLPS [58, 59]), which is more soluble than the free-base crystalline phase (melting point, 
149 °C). Ignoring this [49, 50], the logS-pH data above pH 7 might suggest that the pKa of haloperidol at 37 °C is 
8.0. This would not be in agreement with the pKa 8.29 independently determined at 37 °C [60] and 8.60 at 
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25 °C [61]. Based solely on the solubility measurements, none of the three possibilities can be definitively 
ruled out, and additional investigation might be desirable.  
 
 
  
 
Figure 3. Examples of logS-pH profiles of haloperidol resulting from different salt precipitations, illustrating some 
degree of supersaturation near the Gibbs pKa in the pH 4.1-4.9 interval and the possible formation of uncharged 
aggregates for pH>8 (see text). 
Figure 3c depicts the titration of the haloperidol mesylate salt by either HCl or NaOH. The higher solubility 
in the salt precipitation region (pH 2-4) compared to that in Figures 3a and 3b suggests that the precipitate is 
the mesylate salt of haloperidol. However, the five lowest-pH points (Figure 3c) are not indicative of a 
mesylate salt. At the lowest pH, the data were better fitted with the Ksp corresponding to the hydrochloride 
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salt. Because of the very low pH (<1), it was necessary to invoke a pH electrode junction potential effect 
(jH=+0.35 [45]; cf., Appendix C). This was also needed in the cases of Figure 3b and 3d, for pH  1. In the 
low-pH mesylate example, there is actually a region predicted to contain co-precipitates of both BH.Cl(s) and 
BH.mesylate(s). Figure 3d is an example of haloperidol introduced as the mesylate salt and titrated with either 
mesylic acid or NaOH. The same solubility is evident in the pH 2-4 region as that shown in Figure 3c. The 
precipitous drop in solubility at low pH in Figure 3c arises as a “common ion” effect, namely that in the pH 2-4 
region, the concentration of chloride contributed by the HCl titrant is not high enough to exceed the solubility 
product of BH.Cl(s), until enough HCl had been added to reach the very low pH values (pH<2). 
In Figures 3c and 3d, the unfilled circles were assigned zero weights in the regression analysis. The 
reasonable explanation for their deviancy from the models is due to supersaturation effects. 
Figure 3e is an example of haloperidol introduced as the phosphate salt and titrated with either phosphoric 
acid or NaOH. No way was found to rationalize the three points (unfilled circles) with the lowest pH, so they 
were assigned zero weights. 
It is interesting to note in the haloperidol case study that the order of drug salt solubility (pH 2-4) is: 
mesylate (23 mg/mL) > chloride (5 mg/mL) > phosphate (3 mg/mL). However, the order of the negative log 
salt solubility products is different: mesylate (2.5) < phosphate (3.2) < chloride (3.5). This highlights the 
notion that salt solubility is a conditional constant, depending on the concentrations of both the drug and the 
counterion, whereas the salt solubility product is a true equilibrium constant. 
As is evident, the interesting haloperidol case study invokes several issues where experimental design has 
significant consequences: titrant used to adjust pH, electrode calibration, supersaturation, and possibly 
aggregation (or related phenomena). 
Thiazolyloxamic Acid Derivative 
Figure 4 shows a very complex solubility-pH profile of a surface-active weak acid, N-[4-(1,4-benzodioxan-6-
yl)-2-thiazolyl]oxamic acid, which has two pKas: 1.32 and 10.31, both determined spectrophotometrically [6]. It 
is an example of a molecule, when added as a salt, that becomes more soluble as more of it is added to 
solution, somewhat like the case of amiodarone [24]. The prominent “bump” in the logS-pH profile is 
consistent with the formation of a hexameric anionic aggregate, (HA–)6. The solubility of the ethanolamine salt 
in the neutral pH region is 20.3 mg/mL (pKsp 4.22). Since aggregation is strongly dependent on concentration, 
in the absence of aggregation (i.e., at lower concentrations), the salt solubility would be predicted to be 
2.0 mg/mL (simulated blue curve in Figure 4a). Here, salt solubility depends not only on the amount of 
ethanolamine but also the amount of the conjugate anion, which in turn is affected by the extent of 
aggregation. Pandit et al. [6] also studied other salt-forming counterions, besides ethanolamine. Figure 4a 
shows the calcium salt solubility (dash-dot curve). The calcium salt is quite a bit less soluble than the one 
based on ethanolamine. For the case of calcium, the impact of aggregation is much lessened, as is suggested in 
Figure 4a. 
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Figure 4. N-[4-(1,4-benzodioxan-6-yl)-2-thiazolyl]oxamic acid as an example of complexity of logS-pH profiles of 
surface-active molecules which precipitate both as salts and as uncharged species. 
Another interesting feature of the oxamic acid derivative solubility profile is that between pH 2.5 and 3.5, 
the free acid, H2A(s), and the ethanolamine salt, [HA
-
.(ethanolamine)H
+
](s), co-precipitate. Figure 4b identifies 
three solid phase regions, with boundaries delimited by thin vertical lines. Below pH 2.5, only the free acid 
precipitates. Above pH 3.5, only the ethanolamine salt of the drug precipitates. Between the two boundaries, 
both solids co-precipitate. A rationalization of this phenomenon is that while there is sufficient amount of the 
acid present to form a precipitate, there is simultaneously enough of the negatively-charged acid and the 
positively-charge ethanolamine to exceed the solubility product, to result in the simultaneous formation of the 
second solid. The presence of the hexamer (thick solid line in Figure 4b) mitigates the process, since a lot of 
the negatively-charged acid is tied up simultaneously in the aggregate.  
Acetylpromazine 
Figure 5 is an example of the speciation of acetylpromazine maleate, a weak base with a reported critical 
micelle concentration of 12 mM [62]. The traditional view of simple ionic detergents is that as the 
concentration of added surfactant increases, monomers form until the CMC is exceeded. Further increases of 
the surfactant lead to the formation of micelles with aggregation numbers reaching 50 or higher, whose 
concentration increases, while that of the monomer remains constant. With ionizable drug molecules that 
have surfactant properties, the picture can be more complicated, as illustrated in Figure 5. The water-soluble 
sub-micellar aggregate, (B9H7)
7+ best fits the “bump” portion of the logS-pH profile. The concentration of the 
monomer does not remain constant, and that of the aggregate formation strongly depends on pH, as shown in 
Figure 5b. Ion-pair interactions between chloride and the protonated form of acetylpromazine are also 
suggested at low pH. There may be neutral aggregates above pH 8 (Case 1b in [27]). 
For additional characteristics of the fascinating properties of acetylpromazine maleate, a close inspection of 
the analysis detail summarized in Figures 5a and 5b, and a review of the paper by Liu and Hurwitz [62] is 
recommended. 
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Figure 5. Acetylpromazine as an example of the complexity of logS-pH profiles of surface-active molecules, 
suggesting that care needs to be exercised in interpreting the shapes of the solubility-pH profiles. 
Summary of Issues Raised in the Case Studies 
The above cases were selected as representative examples of apparently well-designed assays, which 
illustrate how complicated heterogeneous chemical reactions involving druglike molecules can get. There was 
much to consider. In several instances, it was important to know the true pKa prior to assessment of solubility-
pH. When ionic strength was excessive, or when very low pH was considered, the calibration of the pH 
electrode required special considerations. Supersaturation had to be recognized and accordingly handled. 
Distortions of the logS-pH curves due to aggregation effects had to be recognized and appropriately 
interpreted. There were surprises regarding the pH range over which co-precipitates (free-acid/base drug plus 
drug salt) could form, parting from the single-pH significance of the “pHmax” or “Gibbs pKa” ideas [42, 43]. It 
needs to be kept in mind that hydrates can form over long equilibration times. Mass spectrometry could be 
used to confirm the aggregate models derived from the computational analysis of logS-pH data. The identity of 
the salt forms of drug precipitates might not be obvious unless the assays were critically designed. More than 
one salt may form over a pH range, and sometimes the salts can overlap over a significant range of pH. Several 
examples of water-soluble drug-buffer complexes were suggested. In systematic testing of salts of a given 
drug, the salt solubility order may not be the same as the Ksp order. The interpretation of the CMC is more 
complicated with ionizable drugs than often recognized. 
Most of the follow-up suggestions that can be made to some of the above cases could be to pursue 
additional corroborative investigations to confirm the presence of aggregates, to identify the stoichiometries 
of the solids precipitating, and the like. Unusual stoichiometry results are seldom confirmed in a different 
laboratory, so reliability of the models proposed can be difficult to assess. Universally, it seems that not 
enough attention had been devoted to the performance of the pH electrodes, particularly at very low pH. A 
definitive discussion of what is meant by “supersaturation” at the molecular level has not been published, as 
far as we are aware. It’s a term that is used frequently and has an intuitive appeal but the exact molecular 
mechanism has not been described. Do transient micelles and/or sub-micellar aggregates, or drug-excipient 
complexes, form in a supersaturated solution? Does meta-stable particle formation, or high energy 
interactions caused by energetic phase contacts, or increased surface tension lead to the supersaturation?  
Examples of poorly designed solubility assays were not considered as case studies. Such assays outnumber 
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the well-designed measurements by a landslide. The goal of this commentary is to present specific 
recommendations that could elevate the quality of assay design, to lead to improved quality of 
measurements, and impart a deeper understanding of the underlying solution chemistry in the presence of 
drug precipitates, and how such solids can influence the interpretation of the solubility measurement. 
Methods for Measuring Solubility 
“Gold Standard” Shake-Flask Solubility Method  
The traditional saturation shake-flask (SF) method is based on simple, easy-to perform procedures, but it is 
time-consuming and labor intensive. Without expensive instrumentation, SF can be conducted in any standard 
analytical laboratory. But to get precise and accurate solubility results, several critical experimental conditions 
have to be considered. When the SF method is properly performed, according to a well-designed protocol, it 
provides high quality data with standard deviation lower than ± 5%.  
The SF method starts with the preparation of a sample suspension, the solution of the tested compound in 
the selected solvent (mainly in aqueous buffer - see the section below) containing a small excess of the solid. 
(A large excess in the pH region where the compound converts from salt form to a free acid/base should be 
avoided, since the disproportionation may result in the free acid/base coating the surface of undissolved drug 
salt, which could result in confusing characterization of the isolated solid state material.) The volume of the 
suspension that should be used depends on the solubility of the sample and the concentration detection 
method. For majority of compounds, when the saturated solution has to be diluted for assay, 1-3 mg in 3 mL in 
small (10 mL) glass vial can be optimal for precise work. In such volume the pH control is easy and one can 
easily follow visually any changes in the vial during the equilibration. For extremely insoluble compounds, 
(S < 10 μg/mL) the concentration has to be measured (when using UV spectrophotometry) without dilution; 
thus bigger volume of solubility suspension (1 mg solid in 15-20 mL solvent) is needed for three replicates of 
sampling or when 5 cm pathlength UV cell has to be used. It is a good practice to measure the pH of the 
solubility suspension 1 h after preparation and readjust the desired pH value if it is shifted which frequently 
happens when compound is applied in salt form (Table 1).  
The heterogeneous system is capped and vigorously agitated (stirred) at a chosen temperature (25, 37 °C or 
other) in a thermostated bath for a specified time (6, 24, 48 h or longer - see the section below) until the 
solubility equilibrium has been reached. After that, the solid is separated from the solution by sedimentation, 
centrifugation or filtration (see below). Upon diluting the sample aliquots with the solvent, if necessary, the 
concentration of the saturated solution is measured by an appropriate method, most frequently by UV-Vis or 
HPLC/UV-Vis. The final pH of the saturated solution is measured.  
Due to the lack of generally accepted standard way to carry out of this method, the published solubility 
studies show great differences in the experimental conditions used [4]. Baka et al. [3] suggested a new 
protocol for SF method using small excess of solid, 6 h stirring and 18 h sedimentation time and running a 
minimum of 3 replicates. This protocol was applied for close to 100 compounds of different structures, acid-
base property, morphology, etc., and found appropriate for the precise measurement of equilibrium solubility 
[63]. 
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Table 1. pH Shift of solubility suspensions upon preparation 
Sample 
pH of BR 
buffera 
pH of BR buffer 
after addition 
of solid (t = 1 h) 
Titrant added to 
readjust the pH 
Final pH of the 
saturated 
solution (t = 24 h) 
Desvenlafaxine 
fumarate 
9.5 5.0 NaOH 9.5 
Promethazine 
hydrochloride 
11.0 6.6 NaOH 10.8 
Quetiapine fumarate 3.0 4.3 H3PO4 3.0 
Rosuvastatin 3.4 4.8 H3PO4 3.5 
             a BR = Britton-Robinson buffer (cf., Appendix A). 
CheqSol Intrinsic Solubility Method 
An alternative to the shake-flask approach for measuring the intrinsic solubility of ionizable compounds is 
the potentiometric acid-base titration method introduced by Avdeef [42]. It is not necessary to separate the 
solid from the solution in the potentiometric approach (cf., Separating Solid from Saturated Solution). The 
intrinsic solubility is calculated from the shift between the apparent pKa (in the presence of precipitate) and 
the true aqueous pKa (in the absence of solid). In order to measure the true intrinsic solubility, equilibrium 
must be reached. This can take quite a long time, especially near the regions of complete dissolution. In order 
to ensure equilibrium is actually reached and in a short time, a method called CheqSol (abbreviation of 
“Chasing equilibrium Solubility”) was introduced by Stuart and Box [64], and subsequently developed by Sirius 
Analytical (UK). The method has been validated [65] and comparison of the intrinsic solubility results measured 
by the SF and CheqSol techniques, when both are properly performed, shows good agreement with a 
weighted linear regression of logS0
SF = -0.13 + 1.00 logS0
CheqSol (r2 = 0.90, s = 0.52, n = 125) [4]. 
The method is based on the shift of the Bjerrum’s plot (cf., Glossary) for the titration when precipitate is 
present (Figure 6). The method consists of dissolving the material in water and seeking precipitation by back-
titrating the resulting solution (adding measured aliquots of base or acid titrant) until first precipitation is 
detected. After initial precipitation of the neutral species has taken place, the solution is switched from 
supersaturated to subsaturated solutions and back again several times, seeking an equilibrium pH where the 
sample is neither further precipitating nor re-dissolving. 
The method quickly pinpoints equilibrium, by advancing the pH further in the direction that it was already 
changing spontaneously. In contrast, the Dissolution Titration Template (DTT) potentiometric method 
passively allows equilibration to be reached [42]. When precipitation is occurring, the pH will change in one 
direction; when dissolution is occurring, pH will change in the opposite direction (see Figure 7). Therefore, by 
following the pH gradient, the appropriate titrant can be added to accelerate pH change in the direction of 
equilibration, above its ordinarily slow change. Inevitably, such titrant additions overshoot the equilibrium 
point, at which point the gradient will be reversed. A smaller amount of the counter titrant is then added. A 
change in pH of less than 0.05 is usually sufficient to reverse the direction of the pH-gradient. Such active pH 
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nudging, termed “chasing equilibrium,” is done as many times as necessary. The interpolated zero points of 
the pH-gradient indicate that the system is at equilibrium, when neither precipitation nor dissolution is 
observed. Each cycle between a supersaturated solution and a subsaturated one will produce a measure of the  
 
Figure 6. Bjerrum curve (average number of associated protons (nH) vs pH) for diclofenac. The experimental data 
follows the theoretical curve up to the precipitation point (full circle), when it jumps onto the precipitation curve. 
The direction of titration is towards the acidic region (right to left). 
intrinsic solubility (Figure 7b). Usually the apparent intrinsic solubility values are distributed in a tight group 
around the average (true) value. If the intrinsic solubility values are not randomly distributed (like in Figure 
7a), and show a systematic drift in either direction, then this means that the equilibrium has not been reached 
(or that a more stable polymorph can be generated), and the number of cycles is increased until the 
equilibrium condition is achieved. In the case of shake-flask measurements the system is allowed to shake for 
6-48 h followed by long sedimentation times (cf., “Gold Standard” Shake-Flask Solubility Method), in an 
attempt to reach equilibrium, which is then assumed. In the CheqSol case it is easy to see if the equilibrium has 
been reached, and it is usually achieved for most compounds in 1-2 h (8 cycles).  
Although not adapted to use auxiliary buffers, the CheqSol technique applies mass balance equations to 
rigorous nonlinear least squares refinement of the model based on the Henderson-Hasselbalch equation. 
However, as described previously in this manuscript, a very accurate determination of the pKa of the sample is 
therefore needed, because the ionization constants will affect the accuracy of the concentration of the neutral 
species, using the Henderson-Hasselbalch relationship. Therefore a very accurate pKa needs to be measured, 
preferably at exactly the same conditions (temperature, ionic strength, ...). 
It is not recommended to use a “predicted” value or a pKa derived from the logS-pH curve (since the 
Henderson-Hasselbalch equation, in many cases, may not be valid). The spread of the crossing points in 
CheqSol is used to determine the coefficient of variation (CV) of the mean intrinsic solubility result, which is 
usually <4%. The final intrinsic solubility value is calculated from an average of several separate experiments 
with 8 cycles per experiment, adequate to provide the intrinsic solubility value with an associated statistical 
reproducibility error (±SD) [1]. 
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Figure 7. Chasing equilibrium of diclofenac (1 of 10 runs): the pH gradient (dpH/dt) changes from a positive value 
(neutral form is precipitating) in the supersaturated region to a negative one (neutral form is re-dissolving) in the 
subsaturated one: the rate of pH change is zero at the crossing points (○). In this run eight cycles were performed (8 
crossing points). Each crossing point in plot a) corresponds to an intrinsic solubility value in b). That is, the first crossing 
point, point 1 in plot a) occurs at around 20 min after the experiment has started, giving an intrinsic solubility value 
(first crossing point) of 1.06 μg/ml (plot b); point 2, 22 min and 1.07 μg/ml; point 3, 26 min, 1.08 μg/ml; point 4, 28 
min, 1.07 μg/ml; point 5, 32 min, 1.06 μg/ml; point 6, 35 min, 1.07 μg/ml; point 7, 37 min, 1.06 μg/ml and point 8, 40 
min, 1.04 μg/ml. Full triangles (▲) represent when acid titrant is added; squares (■) when base titrant is added, (◊) 
mean no titrant added; (○) are the crossing points, when the pH does not change, and the large empty triangle is 
where the experiment starts.  
The measurements are performed under inert gas (argon or nitrogen) and degassed reagents and water are 
used (minimal dissolved CO2). The total ionic strength, I, is kept nearly constant at 0.15 M KCl and the 
temperature is precisely controlled throughout (e.g., 25.0 ± 0.1 oC). The pH electrode is calibrated using the 
“Four-Plus” method (cf., Appendix C).  
Diclofenac is shown below as an example [66]. Figure 6 shows the Bjerrum curve for diclofenac. For fully 
dissolved diclofenac the titration curve is calculated from the pKa of diclofenac (measured previously at the 
same conditions as the solubility experiments) and corresponds to the continuous line in Figure 6. Aqueous pH 
titration was not used to determine the pKa because of precipitation problems. Instead, several titrations were 
performed at different concentrations of co-solvent (methanol) and the aqueous pKa was obtained by 
extrapolation to zero methanol concentration (Yasuda-Shedlovsky method) [27, 67-69]. The average pKa of 
4.08 ± 0.04 was obtained (n=10, Iref = 0.15 M, 25 
oC), which agrees closely with previous reported value of 3.99.  
In the CheqSol method, diclofenac sodium is titrated with standardized HCl (Figure 6, high-to-low pH 
direction), until precipitate is turbidimetrically detected (filled circles). At this point the measurements depart 
suddenly from the calculated Bjerrum curve, because of the change in the amount of dissolved diclofenac. The 
solution is then repeatedly switched (by HCl/KOH titrant additions) from subsaturated to supersaturated 
states (Figure 7), until the value for the transition between the states, the solubility estimate, has converged. 
The intrinsic solubility is calculated as the mean concentration of all the interpolated crossing points. The 
Bjerrum curve for the saturated solution is illustrated as the dot-dashed line in Figure 6. The experiment was 
repeated ten times and a new intrinsic solubility value is calculated as the mean of all ten converged intrinsic 
solubility values. 
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Results for one solubility determination of the sodium salt of diclofenac are illustrated in Figure 7, which 
represents the pH gradient against the concentration of the neutral species. Each crossing point represents the 
transition from supersaturated to subsaturated (or vice-versa) and so the concentration of the neutral species 
at zero pH gradient is the intrinsic solubility (S0) of diclofenac. All crossing points should lie close together and 
give essentially the same answer. The agreement in Figure 7 is excellent, with a coefficient of variation (CV) of 
1.2 %. The spread of these crossing points is used to determine the CV of the mean intrinsic solubility result, 
and as pointed out earlier, to check if equilibrium has been reached. If the crossing points lie closely together 
(low CV) this means that the sample is poised at equilibrium, but if the crossing points are not in a tight bunch 
(high CV) or they are not randomly distributed (showing a tendency towards one single intrinsic solubility 
value) that means that the system needs more time to evolve towards steady state. 
The diclofenac free acid was isolated by stopping the solubility experiment after eight cycles at pH 6.5. At 
this pH and at the end of the experiment (60 min), the solid precipitate is in equilibrium with the neutral form 
in solution. Differential scanning calorimetry, thermogravimetric analysis and powder X-ray diffraction were 
performed on this precipitate in order to fully characterize the solid. The crystal structure of this solid 
corresponded to the structure SIKLIH01 (Cambridge Structural Database) [70]. Characterization showed that 
the precipitated solid is the anhydrous form of the acid of diclofenac, space group C2/c, with an observed 
melting point of 180.5 °C. 
Potentiometric Cycling for Polymorph Creation, [PC]2  
Any solubility measurement depends on the form of the solid in equilibrium with its saturated solution. It is 
therefore not enough to know the solid form of the material at the beginning of the experiment. Using the 
CheqSol method one avoids the possibility of confounding different forms precipitating, and therefore 
reporting misleading data (i.e., amorphous vs crystalline, salts vs neutral forms, hydrates vs anhydrous...). 
Pudipeddi and Serajuddin published a survey in 2005, showing that the difference in solubility of polymorphs is 
usually less than a factor of two [18]. However our results suggest that polymorphs [71] can have a 
considerably greater factor than this. It is therefore of vital importance to properly characterize the solid form, 
the solubility of which is reported, but this is rarely done in the literature.   
CheqSol can be used to parse the entire Meta Stable Zone (MSZ) shown in Figure 8, starting from the first 
form precipitating at high supersaturation, which is the highest energy polymorph (kinetically driven), down to 
the last most stable form on the thermodynamic solubility saturation curve (thermodynamically driven) and 
achieved by cycling the system many times between supersaturation and subsaturation. This transition is 
normally seen as a continuous transition from the first precipitate to the most stable form, following Ostwald’s 
rule (see Figure 8). Metastable polymorphs encountered during this path are not, in general, stable enough to 
isolate and characterize, but sometimes a metastable polymorph arises during this process, being stable 
enough to reach a 100% of this metastable polymorph, which then can be isolated and characterized. 
Nevertheless, if one continues cycling between supersaturated solution and subsaturated solution, this 
metastable form will evolve towards the most stable one, which will not change in form under the cycling 
process. It’s an advantage that these polymorph transformations can be followed in real time, when the 
solubility can be measured for each different form, by stopping the cycling at a specific pH, collecting the solid 
and characterizing it by several techniques. This cycling method has been called “Potentiometric Cycling for 
Polymorph Creation” [PC]2. 
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Figure 8. Supersaturation and Oswald ripening. 
This transformation can also be followed in real time using a Raman probe coupled to the potentiometric 
instrument enabling one to follow these phase transitions without the need of stopping the experiment and 
isolating the solid. This technique allows one to have a precise control of the rate of transformation of one 
form into the other, depending on the conditions of the experiment used.  
 
 
Figure 9. Bjerrum curve for sulindac depicting the first (Form I) and equilibrium cycling (Form II). Figure on the 
right shows the evolution of the pH gradient as the experiment progress. Note how the first precipitate form I has 
a solubility around 70 μg/mL, while the most stable form, Form II, stablishes the cycling on a value around 10 
μg/mL. 
This approach has been applied to numerous compounds (bases, acids and zwitterions), generally obtaining 
the more stable polymorph; in many cases they proved to be newly-identified polymorphs [1, 66, 71-74]. 
Sulindac exemplifies the [PC]2 approach [73]. At first the experiment produced measurements following the 
usual pattern of a CheqSol experiment and the readings converged on an intrinsic solubility of 70 μg/mL 
(Figure 9). The crystalline precipitate (Form I in Figure 9) was then isolated and characterized by powder X-ray 
diffraction (PXRD), Raman spectroscopy, infrared spectroscopy (IR), thermogravimetry analysis (TGA) and 
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differential scanning calorimetry (DSC). The powder pattern for this form (Form I) matched the pattern reported 
in the Cambridge Structural Database (CSD reference code DOHREX) [75]. However, it was observed that a 
sudden drop in solubility from about 70 to 10 μg/mL occurred after cycling for 20 min (Figures 9 and 10). 
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Figure 10. Evolution of pH vs time for the sulindac experiment. Form I is obtained in pure form if the cycling is 
stopped before 20 minutes (precipitation takes place at a pH=4.5). Pure Form II is obtained when the cycling is 
kept for longer times (40-50 min, pH=5.7) 
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Figure 11 Powder X-ray diffraction of the different solid forms obtained during the sulindac [PC]
2
 experiment. The 
first precipitate detected in the experiment is Form I which corresponds to the orthorhombic sulindac Pbca 
already described in the CCDC database (DOHREX). Form II did not match any previously reported pattern. The 
new polymorph of sulindac, form II, is the most stable polymorph and corresponds to the monoclinic P21/c form. 
This new form has now the reference name DOHREX01 in the CCDC database.  
This behavior was repeatable and setting up the conditions to cycle for more than 20 min always produced 
the more stable Form II with an intrinsic solubility of 10 μg/mL. This low solubility form was isolated and 
characterized in the same manner as Form I but in this case the powder pattern did not correspond to 
anything in the CSD (Figure 11). The DSC and TGA measurements confirmed that Form II has no solvent in the 
crystal structure, and therefore it was not simply a different hydrate of sulindac. The crystal structure of this 
new form (II) was solved from the powder X-ray diffraction pattern using the simulated annealing algorithm 
implemented in DASH [76], and refined using the Rietveld method implemented in the General Structure 
Analysis System [77]. The factor of seven fold between the intrinsic solubility of the original form I of sulindac 
ADMET & DMPK 4(2) (2016) 117-178 Consensus Recommendations for Improving Solubility-pH Data Quality 
doi: 10.5599/admet.4.2.292 135 
and this new more stable Form II is unusually large, but based on many other [PC]
2 
experiments performed on 
different materials, a 10 fold difference is quite common. The [PC]
2
 approach is therefore a very promising 
technique to measure accurately and reproducibly the intrinsic solubility of different polymorphs, since the 
approach is able to generate metastable and stable polymorphs. Experiment to produce the hydrate or the 
anhydrous form exclusively (when possible) can be designed. The application of the [PC]
2
 technique to 
polymorphic systems apparently generates the most stable form of the compound, which is especially 
appealing to the pharmaceutical industry. By controlling the experimental conditions, also metastable forms 
can be obtained on purpose.  
Solid State Characterization, Polymorphs, Hydrates, Cocrystals 
Analysis not only of the solution, but also of the solid residue, at least at the beginning and at the end of a 
dissolution experiment, is often claimed to be too time-consuming, to be recommended for common use. 
However, the interpretation of the results of a dissolution measurement can be misleading, if solubility refers 
to the wrong (or unknown) solid phase. Modern powder X-ray diffraction (PXRD) techniques make it possible 
to follow the composition of a solid phase directly in solution in situ, and also in high-throughput screening 
experiments (e.g., using instruments from Panalytical [78], or Bruker [79]). When characterizing a solid sample 
by PXRD, it is important not to limit the analysis by considering one or two characteristic peaks, but to analyze 
the whole diffraction pattern. Diffraction patterns of some polymorphs can be very similar at low values of 2 
diffraction angles, so that they can be distinguished only if data are collected also at higher angles (see as an 
example diffraction patterns of the α, ε, ε’-polymorphs of chlorpropamide, Figure 12 [80]).  
One can also use confocal Raman spectroscopy for fast analysis of the solid phase [81, 82], although Raman 
spectroscopy may be less sensitive for distinguishing between the polymorphs with common structural motifs 
than PXRD is. It is also very instructive to monitor a crystal of a selected original phase directly in solution using 
an optical microscope: quite often a recrystallization into another solid phase can be visually evident (see 
Figure 13 as an example), but that should never be taken as proof of different polymorphs since a single form 
can show multiple morphologies.  
The following example further illustrates some of the kinds of unexpected results that may arise following 
solid-state characterization, which might surprise some practitioners. The differential scanning calorimetry 
(DSC) of a hydrochloride salt of an insoluble base (pKa  9) indicated a sharp negative peak, corresponding to 
the melting point of the drug salt. The salt was added in substantial excess to a neutral solution (where not the 
entire solid dissolved), whose pH was subsequently adjusted to 10. After 24 h, the solid was filtered out, rinsed 
and dried, and had its DSC run. A much lower melting point corresponding to the free base was expected. 
However, the melting point actually measured by DSC was identical to the original drug salt starting 
material. A possible explanation is as follows. When a practically insoluble base (e.g., thioridazine) is added as 
a hydrochloride salt in large excess to a neutral solution, and the resultant suspension is then quickly made 
alkaline (pH>pKa), it is possible that the drug released from the dissolving salt particles immediately re-
precipitates as the free base on the surface of the salt particles, quickly encasing them. These free-base coated 
particles of undissolved salt can be stable in solution. The suspension may reach a steady state after 24 h, 
regulated by the surface coating (which may be amorphous, or crystalline, or oil) of the practically-insoluble 
free base, although the suspension contains considerable undissolved crystalline salt, insulated from the 
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aqueous solution. The filtered solid can show a melting point corresponding to crystalline drug salt, rather 
than the expected free base. This example illustrates the value of solid-state characterization and the need to 
critically examine assay protocols. 
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Figure 12. Powder X-ray diffraction patterns of α- , ε’-, ε- polymorphs of chlorpropamide. Note the similarity of 
the patterns of the α- and ε’- polymorphs at low 2 diffraction angles; zoomed insert enlarges the diffraction 
patterns of 1 and 2 at higher 2 diffraction angles, where the differences are pronounced [80]. 
 
 
Figure 13. Recrystallization of tolazamide polymorph II (large rhombic plates) into another tolazamide polymorph I 
(small elongated prisms) [83]. 
As seen previously (cf., “Potentiometric Cycling for Polymorph Creation”), there can be features in the 
solubility or dissolution curves which can suggest that the composition of the solid phase does change with 
time, and the results at the end of the measurements refer to another phase than at the beginning. This can 
be further illustrated with the example of L-glutamic acid. 
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L-Glutamic Acid Polymorphs 
Figure 14a shows the variation of the concentration of L-glutamic acid in aqueous suspension. One can 
notice, that the saturated concentrations start decreasing after some time. An explanation of this 
phenomenon can be provided by Figure 14b, in which the relative contents of the more soluble polymorph, 
the α-L-glutamic, in the solid phase in contact with solution, is plotted versus time of stirring [84]. 
 
  
Figure 14. (a) Variation of the concentration of L-glutamic acid in aqueous solution versus time at 35 °C and 50 °C. (b) 
The content of the α-polymorph of L-glutamic acid in the solid sample stored in aqueous solution at 35 °C, 50 °C, 70 °C; 
Data from [85]. 
The β-L-glutamic acid is the more stable form of L-glutamic acid [84]. The α- to β-form transition can 
proceed also in the solid state under humid conditions, although very slowly (being far from completion even 
after several months [84, 85]. Interestingly, no transition was observed on heating a dry crystal of the α-form. 
In solution, when the crystals of the β-form precipitate, they deposit mainly on the surface of α-crystals, rather 
than as single crystals suspended in solution and the two forms can fuse into each other to such an extent, 
that their co-existence could be revealed only by PXRD, but not by optical microscopy [84, 85]. 
In Figure 15 the data from Sakata [85], processed using pDISOL-X, are presented in a comparison with 
similarly treated data from Lee et al. [86]. Figure 15a shows the expected parabolic-shaped logS-pH profile of 
L-glutamic acid, without indication of the polymorphic form. From the pDISOL-X analysis of the data, the 
intrinsic solubility, S0, refined to 7.5 ± 0.1 mg/mL. Figure 15b shows the result of a single-point analysis of 
L-glutamic acid, known to be in the β-form [85], where the refined S0 = 7.7 mg/mL. The comparable S0 values 
suggest that Lee et al. [86] had performed measurements on the stable β-form. It is worth pointing out that on 
examination of the Sakata publication [85], one encounters several shortcomings in method description, which 
are, unfortunately, rather common when examining published results. First, solubility has been reported in 
units of “g solute per 100 g water.” Given that 100 mg of NaXH.H2O plus 1 equiv. of HCl had been introduced 
to water, it is not clear, what is meant by “solute”, i.e., which formula weight should be used to convert to 
molality. The result closest to that of Lee et al. [86] suggests that “solute” refers to the zwitterion XH2 species, 
not salt form, NaXH.H2O, that was actually added to the solution. Such ambiguities happen quite often in the 
nearly 850 citations in the solubility database [4]. Clarifications are often not possible, since the authors are 
either no longer active, or the original experimental data cannot be located, or the authors are deceased. 
Second, the final pH value was not reported [85]. For L-glutamic acid, it does not matter much, though 
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knowledge of the pHsat becomes important for low soluble molecules (e.g., mefenamic acid, diflunisal, 
fenbufen, indomethacin, clofazimine, terfenadine) [4]. Using pDISOL-X, the two calculated saturation pH 
values, pHsat, are 3.38 (salt) and 3.37 (zwitterion). Third, the values of ionic strength have not been reported. 
Depending on which formula weight assumptions have been made, the values would be calculated as 0.54 or 
0.64 M, either value well above that of normal saline. 
  
Figure 15. The data from Sakata [85] processed using pDISOL-X in a comparison with similarly treated data 
from [86]. 
Cocrystals  
Interest in pharmaceutical cocrystals emerged rapidly in the last decade [30, 87-96]. Quite often cocrystals 
can be formed in the physical mixtures of the two components even without any action, merely due to 
moisture sorption by components themselves [97], or by a polymer excipient [96, 98]. Presence of cocrystals 
in the drug formulation is thus possible even when not anticipated. Cocrystals are often designed and 
produced on purpose, to increase the solubility, or the stability, or the tabletability of an active pharmaceutical 
ingredient (API) [30, 92, 96, 99-104]. However, when a cocrystal is dissolved, the initially high concentration of 
the API in solution can drop down with time, and sometimes this happens very fast. Cocrystal solubility is 
sensitive to coformer concentration and pH [31]. The presence of surfactants can have a pronounced influence 
on the dissolution of cocrystals. Surfactants are commonly used in pharmaceutical development, in dissolution 
media, as formulation aids, to enhance wetting and solubility of hydrophobic drugs [105, 106], and are, of 
course, encountered in vivo. Whereas the micellar solubilization of single-component crystals has been 
thoroughly studied, micellar solubilization of cocrystals is not well understood. A key question is: how do 
surfactants that solubilize the drug, influence cocrystal solubility and dissolution [33, 96]? The solubility of a 
hydrophobic drug in aqueous solution depends on the total surfactant concentration [33]. Solubility curves of 
a pure drug and a cocrystal intersect at a critical stabilization concentration (CSC) point, which increases with 
coformer solubilization [33]. Cocrystal solubility for cocrystal R-HA in micellar solutions can be predicted from 
Ka and S0 values of cocrystal components (drug, coformer) and Ksp of cocrystal in blank media [28]. 
Cocrystal and drug solubilities converge as they approach CSC [83, 107]. Cocrystal CSC is highly sensitive to 
pH [108]. A key parameter, which enables the measurement of cocrystal solubility and to establish stability 
regions from a single experiment, is the eutectic, or transition point (Figure 16) [28]. At this point, 
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Scocrystal = Sdrug (cocrystal solubility in terms of drug moles); two solid phases are in equilibrium with solution; 
solution composition [B]tr, [A]tr is fixed at T and pH, regardless of ratio of two solid phases [28]. 
 
 
Figure 16. A schematic representation for determining the eutectic, or transition point “Tr” – the point at which 
the “solubility of AB versus concentration of B” curve crosses the “solubility of A versus concentration of B” curve. 
At this point Scocrystal = Sdrug (cocrystal solubility in terms of drug moles), and the two solid phases (AB and A) are in 
equilibrium with the solution. The solution composition [B]tr, [A]tr is fixed at T and pH, regardless of ratio of two 
solid phases. Adapted from [28]. 
Carbamazepine-Nicotinamide Cocrystal  
Figure 17 [108] illustrates the fast drop in the carbamazepine concentration, as indicated by the shift in the 
UV absorption maximum, on dissolution of a carbamazepine-nicotinamide 1:1 cocrystal in water. Two minutes 
after the start of the dissolution of the carbamazepine-nicotinamide cocrystal, the solid sample transforms 
almost completely into the carbamazepine dihydrate, with a significantly lower solubility, and the 
concentration of carbamazepine in solution drops. Cocrystal solid-solution equilibria are dictated by solution 
composition. If anhydrous carbamazepine is dissolved in the solution of nicotinamide, a 1:1 cocrystal is formed 
[108]. 
 
Figure 17. Transformation of a cocrystal of carbamazepine with nicotinamide into carbamazepine dihydrate on 
dissolution (monitored spectroscopically). Data from [108].   
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Cocrystal Solubility-pH Profiles 
Cocrystals can impact pH-dependent solubility even when the drug is nonionizable. The pH dependence of 
the solubility of a cocrystal can differ significantly from that of a pure drug compound, the curves being 
qualitatively different for ionizable/non-ionizable/zwitterionic API and amphoteric/basic/acidic coformer [31]. 
Figure 18 illustrates this using as examples the solubility of the carbamazepine – salicylic acid 1:1 cocrystal 
(Figure 18a) and of the carbamazepine-4 amino-benzoic acid hydrate 2:1 cocrystal (Figure 18b) as functions of 
pH, and, for a comparison, the pH independence of the solubility of the pure drugs [31]. 
 
  
Figure 18. (a) The solubility of the carbamazepine – salicylic acid 1:1 cocrystal, and (b) the solubility of the 
carbamazepine - 4-aminobenzoic acid hydrate 2:1 cocrystal as functions of pH. The dashed lines are the expected 
solubilities of the pure drugs [31]. The data from [31] have been processed using pDISOL-X. 
The data from Bethune et al. [31] have been processed using pDISOL-X. This procedure has given almost 
the same Ksp value for the carbamazepine – salicylic acid 1:1 cocrystal as reported in [31], but it was necessary 
to introduce a complex between carbamazepine and salicylate anion. To interpret the curve with the minimum 
for the carbamazepine – 4-aminobenzoic acid hydrate 2:1 cocrystal, one needs to consider cocrystal 
dissociation and coformer ionization. 
 
ADMET & DMPK 4(2) (2016) 117-178 Consensus Recommendations for Improving Solubility-pH Data Quality 
doi: 10.5599/admet.4.2.292 141 
 
Analysis of the Species in the Saturated Solution using Mass Spectrometry 
Mass spectrometry is a powerful technique to obtain information about the species present in any solution, 
including saturated solutions [53]. In solubility assays, apart from the compound itself, the presence of 
charged aggregates can be detected by direct infusion into the mass spectrometer of the saturated solution, as 
demonstrated for cefadroxyl by Shoghi et al. [53] (cf., Figure 2a). With a simple mass spectrometer (i.e., an 
electrospray ionization source and a single quadrupole) aggregates with a molecular mass up to 1500-2000 Da 
can be easily observed. In addition, the use of more sophisticated instruments, like triple quadrupoles or high-
resolution mass spectrometers allows the confirmation of the presence of aggregates through the product ion 
scan or the exact mass measurement of the aggregates. 
One important requirement in the measurements when buffered solutions are used is that buffers must be 
MS compatible. Thus, buffers based on compounds such as formic acid, acetic acid, lactic acid, carbonic acid, 
ammonia, or ethylenediamine are recommended. It is helpful to report buffer concentrations in mM units. 
Another compulsory caution is to avoid the formation of aggregates in the ionization source. This drawback 
can be easily overcome by raising the declustering potential of the source to high voltages (up to ± 200V, 
depending on the ionization mode). Under such conditions, much more fragmentation is observed, but in case 
aggregates are detected it is ensured that they come uniquely from the sample itself. 
Recommendation for Solid State Characterization  
It is recommended that the solid sample for which solubility is measured be evaluated by powder X-ray 
diffraction (PXRD), both before and after the solubility assay. If possible, it is preferable to monitor the 
sample directly in solution (modern PXRD instruments specially adapted for the needs of pharmaceutical 
industry make this possible). If, however, such an in situ measurement is not possible, the conditions of 
separating the solid from solution, drying and preparing the sample for PXRD (e.g., manual grinding in a 
mortar) must be specified and standardized with utmost care. Quite often, phase transition, dehydration, 
or transformation (in a multi-component system) can occur on drying, grinding, tableting, or storage. It is 
recommended that the PXRD pattern be measured in a broad enough range of 2 diffraction angles and 
analyzed as a whole, not just by searching selected peaks, and where possible samples should be loaded in 
capillaries for data collection so we minimize preferred orientation peaks.  
Confocal Raman spectroscopy can be recommended as a complementary – though less unambiguous – 
tool to control possible changes in the phase and chemical composition of the solid phase. 
DSC and TGA analysis of the sample is recommended before and after the experiment. Note, that even 
very similar DSC curves cannot completely exclude that the samples have different phase composition.  
Analysis of the final solid phase is desirable in all cases, since the form precipitating can be, and usually 
is, different from the form introduced at the beginning of the study, and becomes critical if some 
“anomalies” in the solubility-pH/time profile are observed. Careful data processing can give insights in 
potential changes in the phase composition during the solubility measurement, and also in the solid state.  
The latter can be verified by PXRD. 
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Although MS provides a clear view of the solutes in solution, it is important to notice that not all type of 
compounds are susceptible to be ionized in certain conditions (especially in absence of organic solvents). 
Other complementary techniques should be considered for solution characterization of those compounds that 
do not ionize easily, form neutral aggregates, or have a high aggregation number such as micelles, among 
others. 
Types of Solubility 
Water Solubility, Sw, and its Relationship to Intrinsic Solubility, S0 
The solubility in water, Sw, is frequently reported for ionizable druglike substances. The procedure calls for 
adding an unspecified “excess” solid (ideally, the free-acid or free-base, not the salt) to distilled water, 
followed by the measurement of the substance concentration after equilibration. Frequently, pH of the 
saturated solution, pHsat, is not reported (and probably not measured). Usually, the reported experimental 
details are incomplete, and so such measurements can have substantial uncertainty. It is useful to consider the 
relationship between Sw and the intrinsic solubility, S0, the value an ionizable molecule indicates at the pH 
where the molecule is completely uncharged (pH<<pKa for acids or pH>>pKa for bases; cf., Appendix B).   
When a relatively soluble weak acid/base is added to water, the pH of the suspension is altered by the 
ionizing molecule, in the direction where the molecule remains largely in the uncharged form: Sw ≈ S0, provided 
the compound is added as a pure free acid/base. For compounds added as salts, it is frequently not possible to 
deduce S0 and pHsat from just Sw and pKa, since the total amount of added compound can affect the disposition 
of the saturated solution: if not enough of the drug salt is added (i.e., salt solubility product not exceeded), the 
solid disproportionates to the free acid/base in the saturated solution, with pHsat depending on the weight of 
drug salt added [11]. 
If the ionizable compound is practically insoluble, then the measured value of Sw can be quite different from 
S0, since not enough of the compound dissolves to alter the pH in the direction of maintaining a nearly 
uncharged molecule in the poorly-buffered solution. If the pKa is known and the Henderson-Hasselbalch (HH) 
equation is valid in the particular case, it is possible to calculate the pHsat, as well as S0. For a one-pKa molecule, 
logS = logS0 + log[10
±(pHsat–pKa) + 1 ] (‘±’ is ‘+’ for an acid and ‘-‘ for a base). Additional Henderson-Hasselbalch 
equations for ampholytes and multiprotic acids and bases are tabulated in Table B.1 in Appendix B [21, 27]. 
When measured compounds contain protogenic impurities, the pHsat may be affected substantially under 
poorly-buffered conditions, which could lead to a change in the measured Sw. Under such circumstances, the 
calculation of S0 from Sw may be quite inaccurate. 
Abraham and Le [109] discussed the relationship between the measured Sw and S0, and identified under 
which circumstances large differences are expected between the two values. The authors derived useful plots 
of S0/Sw vs. logSw for acids and bases over a range of pKa values. For example, for ionizable acids with pKa 5 and 
Sw>0.001 M, or with pKa 3 and Sw>0.1 M, the water solubility is practically equal to the intrinsic solubility. The 
same is true for ionizable bases with pKa 10 and Sw > 0.01 M, or pKa 8 and Sw>0.0001 M. 
When the aqueous solubility of practically insoluble free bases (pKa>9) is measured in water, the pH is only 
slightly affected by the minute extent to which the base dissolves. To a much greater degree, the measured pH 
is regulated by a much stronger buffer present in water, namely, dissolved carbon dioxide. This is often not 
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factored in. In the (unlikely) absence of CO2, the drug-saturated solution may be at pH>9. But the presence of 
dissolved CO2 can lower the pH<6, depending on the level of CO2 and how insoluble the basic compound is. 
Rytting et al. [110] reported logSw=-4.87 for terfenadine dissolved in water, with no further information. If 
ambient [CO2] = {0, 10, 20} μM, the calculated logS0 = {-5.7, -6.3, -8.3} and pHsat = {9.2, 8.5, 6.6}, respectively. 
Consequently, the error in the calculated S0 of practically insoluble basic drugs in water is expected to be 
enormous (up to 3 log units), since it is very difficult to eliminate CO2 entirely simply by bubbling an inert gas 
(Ar, N2, He) through the solution. Furthermore, any protogenic drug impurity in water under the circumstances 
would also lead to large uncertainties in the HH-calculated S0. That is why one ought to actually measure the 
pH of the saturated solution. But, measuring the pH accurately of an unbuffered solution is another problem, 
due to the effects of uncontrolled electrode junction potentials and possibly inappropriately calibrated pH 
electrodes [27]. The addition of a background electrolyte (e.g., 0.15 M NaCl) would lessen the junction 
potential error. 
Solubility in a Single Buffered Solution, SpH 
The use of a buffered solution lessens some of the uncertainties associated with pH measurement and the 
impact of trace impurities. The pH of the saturated drug solution still needs to be carefully measured after 
equilibration. Still, to convert the SpH to the intrinsic value, S0, it is necessary to know the independently-
measured pKa and the application of the HH equation (provided it is valid for the studied molecule). 
Intrinsic Solubility, S0, from Multiple logS-pH Measurements 
When critically comparing the solubility of different molecules, the intrinsic value is the appropriate one to 
consider. The most general way to determine the intrinsic solubility, S0, requires multiple pH measurements 
using the SF method. Ionizable/nonionizable drugs may be considered, as well as reactions that form drug 
salts, complexes, aggregates/micelles, or cocrystals. CheqSol is also a good way to determine intrinsic 
solubility of ionizable drugs. Interferences due to buffers, salts, or complexing agents are generally avoided.  
Several of the preceding case studies illustrate how complicated the analysis of logS-pH can be. When 
measuring several different logS-pH points, both below and above the pKa (and pKa
Gibbs
 with drug salt 
precipitates), it is not necessary to rely on simple HH equations (which might not accurately predict the logS 
dependence on pH). Buffers may be required to cover the regions of pH poorly buffered by the drug molecule. 
Also, buffers may facilitate the uniform pH adjustments of the solutions using standardized titrants. 
Other Solubility Terms Used in the Literature 
Other solubility terms (e.g., biological, native, natural, unbuffered, turbidimetric, kinetic) are used in the 
literature. We encourage practitioners to give careful consideration to the meaning of the terms used to 
associate with solubility. At times these lesser-common terms have been used without critical definition or 
sufficiently rigorous measurement practices. 
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Temperature 
Solubility is a function of temperature, so the assay temperature always needs to be reported. It is 
advisable to measure and record the actual temperature in the sample vessel during the equilibration period. 
Or better yet, the measurement is performed in a thermostated vessel kept at 25/37 °C. It is clear that 
unspecified “room temperature” can be different from laboratory to laboratory, and in some cases, seasonally 
variable. 
When solubility measurements are conducted at different temperatures, it is common to report the 
solubility values in mole fraction, mass fraction, and molality units, since these do not depend on the density 
of the solutions, which can change with temperature. Since advanced computational approaches to evaluate 
the logS-pH data are anchored in molarity units, it would be useful to report the weight of a certain volume of 
the saturated solution at the assay temperature, after the solid had been separated from it, so that molality 
units can be converted to those based on molarity. 
 
 
 
Recommendations for Type of Solubility to Measure 
Generally, the measurement of the water solubility, Sw, cannot be recommended. If there is good 
reason to do so, then (a) use freshly distilled/purified water that had been allowed to equilibrate at the 
measurement temperature, (b) measure the pH of the water exposed to ambient air, pHw, before adding 
the sample (to estimate CO2 concentration), and (c) measure the final pHsat. Sample purity needs to be 
verified. 
Potentiometric methods such as CheqSol are well suited to determine intrinsic solubility (avoiding the 
possible interferences due to buffers), and can thus be well recommended. 
Multiple-pH shake-flask assays are recommended for general applications, since many different solution 
properties can be revealed by the logS-pH profiles. A single solubility determination at a measured pH can 
establish the intrinsic solubility. But it is recommended that at least three pH points be measured if the 
intrinsic solubility is to be determined reliably: pH = {pKa - 2, pKa, pKa + 2}, where pKa is independently 
determined.  If also the salt solubility is being determined, then more points would be required: e.g., 
pH = {pKa
Gibbs
 - 2, pKa
Gibbs
, pKa
Gibbs
 + 2}, in addition to those points around the pKa. The characterization of 
drug salts, aggregates/micelles, complexes, and cocrystals generally requires multiple-pH solubility data, in 
thoughtfully-designed assays.  
Recommendation for Reporting Temperature  
The temperature must always be measured at the time equilibration is established, and its value 
reported in the publication. The method of temperature control should be reported. It is not helpful to 
state the value as “room temperature.” 
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Ionic Strength 
Measured solubility can be affected by ionic strength (especially when salt solubility is measured), so the 
ionic strength usually needs to be reported. The average total ionic strength needs to be calculated from the 
contributions at each pH point. It is the pH-dependent sum of the contributions of inert background 
electrolytes (NaCl, KCl, etc.), buffer constituents, as well as the sample (especially when introduced in salt 
form). It is not possible to back-calculate the ionic strength at each pH point if the report simply states that 
“buffers were used” or “measurement was done in water.”   
 
 
Measurement of pH using Glass Electrodes 
A pH electrode is a sensitive electrochemical probe that can indicate the degree of acidity of a solution. The 
device is a combination of a reference half-cell (in a compartment separated from the test solution by a 
porous-barrier junction that permits the flow of an ionic current but prevents convective mixing of the 
reference and the test solutions) and a pH-sensing glass electrode half-cell. The two half cells immersed in the 
test solution complete the electrical circuit, as a high impedance (i.e., extremely low electrical current) voltage 
is measured, which is proportional to pH of the solution. Such a system needs to be calibrated against 
solutions of defined pH, so that the measured voltage can be converted to the “operational” pH scale. The 
latter is nearly, but not precisely, the activity scale, paH [27]. The relationship between voltage and the 
operational pH depends on temperature and ionic strength.  
For common laboratory use, the pH electrodes are typically calibrated against standard (“NIST-traceable”) 
pH 4.00 (phthalate) and 7.00 (phosphate) buffers, with ionic strength of 0.10 M. However this procedure may 
be inadequate for specialized applications, such as pKa determination and solubility-pH measurement. 
Solubility determination may involve measuring pH in solutions with near zero ionic strength or ionic strength 
as high as 1 M, far from the 0.1 M value of the calibrating buffers. The reference electrode part of the circuit 
can develop significant porous-barrier junction voltages (“liquid junction potentials,” LJP) when immersed in 
solutions with near zero ionic strength or with pH < 2. Also, the glass bulb of the sensor can develop 
mechanical stress when dipped in strongly acid solutions (pH<1). Both effects contribute to an error in pH 
reading, which can be as high as a pH unit [4].   
In published solubility studies, the electrode calibration is virtually never described and the brand of 
Recommendation for Reporting Ionic Strength  
The total ionic strength, averaged over the pH range of the assay, needs to be reported.   
If the computer program used to evaluate the logS-pH data does not calculate the ionic strength, then 
the report must give enough information about the solution composition so that the average total ionic 
strength can be independently calculated – i.e., precisely state: (a) concentration and type of ionic strength 
adjustor used (e.g., 0.15 M NaCl), (b) precise stoichiometry and weights of buffer used (e.g., 
Na2HPO4.12H2O, not just “sodium phosphate”), (c) weight and form of sample used (e.g., amiodarone 
hydrochloride), (d) any other relevant electrolytes that would contribute to the ionic strength calculation. 
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electrode used is largely unidentified. In contrast, attention to such detail is the norm in pKa determination 
practice, where specialized calibration methods are well developed [22, 27, 44, 45, 111-113]. Researchers who 
determine pKa values using commercial analyzers are well acquainted with the four-parameter electrode 
standardization procedure, described in Appendix C. Those using the Sirius Analytical titrators will recognize 
the procedure as the “Four-Plus” method, and those using the Pion titrators will recognize it as the “ABC” 
method.  
  
 
Buffers 
A pH buffer is a solution which resists pH change when a small quantity of an acid or a base is added to it. 
For example, a 50 mM phosphate buffer solution at pH 6.8 has a “buffer capacity” of 27 mM/pH. That is, to 
change pH of a 1 mL buffer solution from 6.8 to 6.7, it would take 5.4 μL of 0.5 M HCl. Distilled water has the 
buffer capacity < 0.005 mM/pH. So, to change the pH of distilled water from 6.8 to 6.7 would require 
< 0.001 μL of 0.5 M HCl. The minimum volume addition from dispensers in commercial pKa analyzers would 
produce at least a pH 2.1 jump in the pH 5.8-8.4 interval in distilled water.   
A surprising number of investigators prepare a standard buffer solution of a known pH, but then neglect to 
measure the actual pH of the drug-buffer slurry when equilibrium is reached. In common practice, buffers can 
be used to set the pH of an assay solution to a desired value. The pH change due to the introduction of drug is 
not zero, however. It depends on the capacity of the buffer solution and the ionization characteristics and 
amount and solubility of the added drug. Even with a buffer solution, the pH can change by several units upon 
the addition of an ionizable substance. See Table 1 for examples.      
Adjusting pH in Multi-pH Solubility Measurement using a Titrant  
There are many different ways to prepare multiple-pH solutions in solubility applications. The pH of the 
solubility medium can be modified using a standardized titrant, which can be a strong electrolyte, HCl/NaOH, 
CH3SO3H, CF3COOH, or a moderate electrolyte, like CH3COOH, H3PO4, tartaric acid, L-lysine, etc. Even though a 
buffer of a known pH is used, let’s accept that the final pH of a fully-equilibrated drug-saturated solution has to 
Recommendations for pH Electrode Calibration 
It is recommended that research-grade combination pH glass electrodes be used. It is a good idea to 
identify the brand and make of the electrode. The calibration procedure used needs to be concisely 
described. Ideally, the four-parameter electrode standardization procedure is recommended [45]. Simpler 
procedures may be satisfactory, as long as they are described precisely.  
The reported pH should be on the “operational” pH scale. The standardization procedure can be used to 
convert pH to the “concentration” scale, pcH, which is used in equilibrium quotients, as described in 
Appendix C. 
Particular attention should be given to the pH electrode calibration when extreme pH is measured 
(pH<1 or pH>12) or when the ionic strength reaches high values, as in the case of salt solubility 
measurement, or near zero values (in unbuffered solutions). 
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be actually measured.   
One way (the most popular) is to look up standard buffer recipes and make the buffers to the desired pH. 
(Many of these prepared buffer solutions are commercially available.) This may seem like a time-saving 
approach, but the choices of buffers may be inappropriate and may make the analysis of the logS-pH profile an 
unnecessary challenge. If many different ingredients are selected to cover the pH range, instances of drug-
buffer interactions may be problematic (Figure 2a, [53]). Choosing concentrated buffer solutions can lead to 
greater drug-buffer interactions and excessively elevated ionic strengths in the final solutions. Drug-buffer 
complexes raise solubility, while drug-buffer precipitates decrease solubility. Some buffers, such as phosphate 
are not compatible with mass spectrometry [53]. Some buffers have too high a UV absorbance. Boric acid 
buffers can covalently interact with 1,2-diol portions in drug molecules. Some combinations of buffers have 
cross interactions: e.g., phosphate and ethylenediamine buffers can form ion-pairs [45]. The optimal choice of 
buffers requires some experience. 
Another way (less popular) is to avoid buffers altogether. After all, the ionizable drug being studied can act 
as its own buffer, particularly if the drug molecule has multiple pKa values. So, self-buffered solutions with 
excess solid can be adjusted to different values of pH by additions of HCl or NaOH. This is actually not a bad 
approach, since interferences due to drug-buffer interactions are eliminated. The downside of this approach is 
that some sparingly soluble drugs may have virtually no buffer capacity over a wide pH range, so that 
impurities may have an inordinate sway over the equilibrated pH. Not using auxiliary buffers would not be 
recommended when studying practically insoluble bases with pKa > 8 (e.g., terfenadine, chlorpromazine, etc.), 
since reading and adjusting pH may be problematic experimentally. 
The third way (occasionally used) is to start with a “universal” buffer mixture of several individual buffer 
components. This mixture can be very beneficial, since the buffer capacity remains above a certain minimum 
level across the whole pH range. For example, the Britton-Robinson buffer (acetic acid, phosphoric acid, boric 
acid, 40 mM each) has an initial pH 1.9 [22]. It is quite simple to adjust the pH to any higher value, simply by 
adding a known amount of 0.5 M NaOH (titrant). 
Constancy in ionic strength across the pH range of interest is also desirable, but most universal buffer 
formulations fall short of that goal (cf., Appendix A). Most investigators using universal buffers pick them from 
well-tested published recipes. (Commercial sources of such solutions are not common.) Since the universal 
buffers were not specifically designed for solubility measurements, their characteristics may not be optimal, 
for the same reasons as mentioned above (drug-buffer interactions, excessive ionic strength, excessive 
computational complexity in data analysis, etc.). 
The fourth way (newly explored and quite promising) is to take the best of the idea of universal buffers, but 
reduce the factors leading to drug-buffer complications noted above. Such new buffers may be called 
“Minimalist Universal Buffers” (MUB).   
Minimalist Universal Buffer (MUB) Formulation 
Traditionally, universal buffer design required a lot of experiments to be performed to come up with the 
desired formulation. Predicting the characteristics of universal buffers computationally would have been quite 
a challenge then. Now that such computational approaches are possible, universal buffer designs specific to 
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solubility-pH applications can be explored easily. In the recent study of the solubility-pH of terfenadine, a MUB 
made of lactic acid and ethylenediamine was tested successfully [114]. 
In a solubility-pH assay, only the regions low in buffer capacity need a boost from an auxiliary buffer. It can 
be computationally predicted (e.g., pDISOL-X) what buffer capacity the drug itself contributes to the solution in 
the pH range of interest [22-25]. The pH regions of unacceptably low buffer capacity can suggest which 
auxiliary buffer to use. Without the capacity boost, it would be impractical to add the extremely small volumes 
of the NaOH/HCl titrant to adjust the pH in 0.2 increments across the low-capacity region.  
In the terfenadine example [114], two such regions were identified. A MUB consisting of just two 
components, 10 mM lactic acid and 10 mM ethylenediamine, filled in the buffer capacity holes. Terfenadine 
lactate was not expected to precipitate, since the lactic acid concentration was low enough. HCl was used to 
lower the pH to 2, and the chloride salt of terfenadine was characterized in the pH 2-5 region. The ionic 
strength was kept well under control.  
Figure A3 in Appendix A shows the region above pH 5 for haloperidol where ethylenediamine was a useful 
added buffer. There, the steepness in the titration curve was lessened by the added buffer. For haloperidol 
without such a capacity boost, the reading of pH > 5 would have been a challenge due to low ionic strength 
and the concomitant junction potential effects. Also, adjusting pH in increments of 0.2 in that region would not 
have been feasible with typical dispensers and titrant concentrations. 
   
 
Ionization Constant (pKa) 
High-quality logS-pH data are measured so that a reliable value of the intrinsic solubility, S0, as well as of 
equilibrium constants of any self-aggregates, micelles, drug-buffer complexes, and of the salt or cocrystal 
solubility products, Ksp, can be determined. The pKa is required in the calculations. There were several 
Recommendations for Buffer Use 
Multiple-pH assays using buffers are recommended for general applications. In reporting solubility-pH 
results, state precisely which buffers were used: in which salt forms and at what concentrations. This is 
needed information for calculating the total ionic strength at each point.  Note that the use of a high 
capacity buffer does not eliminate the need to measure the equilibrium pH of a saturated solution. 
Sufficient buffering is needed so that pH can be measured reliably and that the titrant can be dispensed 
precisely to set the desired pH. Ordinarily, relatively low buffer concentrations (e.g., 5-25 mM) can be 
recommended. Use of higher concentrations need to be critically justified. The sample itself may be an 
adequate buffer. It is not beneficial to overload the assay protocol with added complications arising from 
unintended buffer-drug interactions. The use of universal buffers (e.g., Britton-Robinson, Sorensen, 
McIlvaine – cf., Appendix A) can be very convenient, but one must guard against unintended/unnecessary 
complications. Some buffer components may cause difficulties in UV or mass spectrometry measurement. 
The MUB approach merits further considerations, since many of the down-sides of buffer use can be 
designed out. 
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examples in the case studies of how critical it can be to know the accurate pKa. The temperature associated 
with the pKa needs to match that of the solubility assay. Also, the “reference” ionic strength, Iref, in data 
analysis needs to be set equal to the ionic strength at which the pKa was determined.   
In the older literature, sometimes the pKa had been determined from logS-pH data [49, 50]. The required 
assumption is that the Henderson-Hasselbalch accurately describes the logS-pH curve. The assumption is not 
valid in many cases, and thus the method can result in large systematic errors in the pKa value (cf., Figure 2c).  
It is far more reliable to use purpose-designed pKa measurement techniques (e.g., potentiometric, 
spectrophotometric, or capillary electrophoretic), under conditions where ionic strength is well controlled and 
complications due to sample complexation, self-aggregation, or precipitation are demonstrably avoided. It is 
felt that commercially-available pKa prediction programs are not accurate enough for use in the interpretation 
of experimental logS-pH data. 
It is quite important that when the pKa of a sparingly-soluble drug is determined at 37 °C using the 
cosolvent extrapolation method, that methanol not be used as the organic solvent. It is highly volatile, and 
systematic errors can confound the determination, which sometimes can be difficult to recognize. A suitable 
solvent alternative is n-propanol. However, if the pKa assay can be performed rapidly (< 3-5 min), the amount 
of methanol lost may be small at 37 °C. (When using methanol-water solutions, it could be prudent to measure 
the final solution volume, e.g., by weighting the vial before and after the assay.)  
 
 
Equilibration Time and Stirring Protocol  
One of the most important experimental conditions of determination of equilibrium solubility is that in the 
solubility suspension, the system has to achieve the equilibrium state. That is, when the dissolution rate of the 
solid is equal to its precipitation rate from the solution. This dynamic equilibrium can be maintained only by 
the presence of solid in the system. Perturbation, like filtration can invalidate this condition.  
The optimal time of equilibration (also called incubation time) in the SF method is difficult to specify and is 
often a debated topic. The equilibration time is mainly determined by the dissolution rate of the compound, 
which depends on many factors like morphology, crystallinity, and particle size. The fine micro-crystals dissolve 
more quickly than large ones; amorphous solids dissolve faster than crystalline substances. The optimal time 
valid for every compound cannot be specified. So the best practice in the most rigorous application of the SF 
method is to check the required incubation time from compound to compound. However, in a standard 
protocol suggested for routine measurement, a generally accepted equilibration time would be useful. In a 
Recommendations for pKa Determination 
The determination of the pKa solely from solubility-pH data cannot be recommended.   
It is recommended that methods specifically designed to determine pKa of very poorly soluble molecules 
be used (e.g., state-of-the-art UV spectrophotometry, capillary electrophoresis, potentiometry). These 
methods are widely available and have been fine-tuned for the challenge. Commercial pKa instruments 
based on the above three technologies are generally well-supported by their manufacturers. 
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comprehensive study – among other factors – the effect of incubation time was tested on the equilibrium 
solubility of model compound, hydrochlorothiazide [3]. The achievement of equilibrium was divided into two 
different steps: vigorous agitation of solubility suspension with stirring and sedimentation. First, the time of 
stirring was varied between 0.5 and 48 h, followed by constant time sedimentation. Second, after 48 h of 
constant stirring time, the sedimentation was varied between 1 and 24h (Figures 2 and 3 in [3]). The study 
revealed that sedimentation is an indispensable part of incubation, because during the intensive stirring, a 
supersaturated solution can form, which needs adequate time in a resting state to form the true equilibrium. 
Based on these results 24 h incubation time (6 h stirring followed by 18 h sedimentation) was suggested as a 
general protocol.  
It may be noted that practically insoluble compounds which consequently have very slow dissolution rates 
may require much longer dissolution time. The unusually high standard deviation of solubility obtained by the 
above standard protocol may be an indicator of the problem. In such case, a series of repeated measurements 
with increasing agitation time would be necessary until the solubility is no longer changing. Some reported 
extremely long equilibration time (e.g., 10-30 d) set up several problems: decomposition of the sample, 
molding of the buffer, changing the pH, evaporation, difficulty in temperature control, etc. Methods 
shortening the incubation time are known but not widely used in the practice [115]. 
 
 
Separating Solid from Saturated Solution  
Three alternative techniques (sedimentation, centrifugation, and filtration) can be used for the separation 
of the solid from the saturated solution before aliquots can be taken out for concentration measurement. A 
recent survey [4] showed that in majority of papers the means of separation used has not been indicated. 
Where even declared, the filtration was the most frequent method (44 %), while centrifugation (14 %) and 
sedimentation (9 %) were less used.  
In the shake-flask method, sedimentation is the primary method of choice, because it assures the 
precondition of dynamic solubility equilibrium, without disrupting the heterogeneous system (see above). At 
the same time, direct sampling from the clear supernatant is simple and fast. The aliquots taken out must be 
completely transparent, and free of any solid particles. If compound properties hinder the formation of clear 
Recommendations for equilibration time 
The use of intensive stirring for agitation followed by sedimentation to reach the solubility equilibrium is 
recommended. The optimal speed of the stirrer depends on the volume of solubility suspension and the 
characteristics of the solid.  It should provide high surface contacts of phases and avoid the formation of 
stable colloid system. 
As a good average time of incubation, 24 h (6 h stirring and 18 h sedimentation) can be recommended 
for overwhelming majority of compounds. In case of very sparingly soluble compounds, it is recommended 
that the suitability of the selected equilibration time be verified.  It is reasonable to start with a 6 h stirring 
time, and check whether the sample concentration is continuing to decrease at longer times. 
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solution upon sedimentation resulted in opalescent solution, centrifugation can be the alternative separation 
method. For such samples centrifugation at ~1000 g (~2000 rpm) for 10 min can be suggested. Procedure 
should be repeated if necessary. 
Surface Adsorption by “Just-Saturated” Sample Solution 
For some compounds the adsorption to vials (glass or plastic) is a problem, especially with lipophilic bases 
and neutral molecules in weakly buffered solutions, as described by Palmgrén et al. [116]. It can be viewed as 
a partitioning phenomenon. Pretreatment of the vial surfaces with subsequently-discarded drug solution may 
be expected to saturate the “binding” sites on the glass or plastic surfaces, thus potentially mitigating the 
problem in subsequent solution transfers.  
In the case of practically insoluble drugs, when solid is separated from slurry, the resulting “just-saturated” 
sample solution can decrease in concentration with each subsequent transfer, as surface adsorption removes 
some of the compound from solution, taking the system further away from the “just-saturated” state, since 
there is no solid to re-equilibrate the perturbed solution. In filtration, adsorption to filters is well recognized 
problem [117]. However, centrifugation as a method for separating solid from saturated solution is not free 
from similar adsorption effects. Consider the Bergström et al. [118] study where centrifugation was done 
twice: “The excess solid was separated from the solution by centrifugation at 23 000 g for 15 min. After the 
centrifugation, approximately 0.25 mL of the supernatant was sampled with Pasteur glass pipettes and 
dispensed into glass insert vials. These vials were placed in Eppendorf tubes and centrifuged for 15 min a 
second time to obtain complete separation of the solution and the remaining solid. After the centrifugation, the 
supernatant was withdrawn with Pasteur pipettes and dispensed into glass HPLC vials. Glass was used 
throughout this procedure to minimize the risk of underestimating the solubility owing to adsorption of the 
drugs to plastics.” It was not explicitly reported that the Pasteur glass pipettes and HPLC vials were pre-treated 
with sample before use. Table 2 lists the intrinsic solubility values of twelve practically-insoluble drugs taken 
from the above study, and compares them to corresponding averaged intrinsic solubilities taken from other 
published studies (with all values normalized to 25 °C [26]). 
Figure 19 is a plot of the above comparison. Notably, the logS0 values from [118] are 1-3 (or more) log units 
lower than the average values reported from other published studies, with the exception of that of 
itraconazole. Although there may be a number of plausible explanations for the differences, it might be useful 
to consider the possibility that the double-centrifugation step led to under-estimated solubility, due to 
adsorption to the glass surfaces of the transfer vials. In the case of itraconazole, the value reported by 
Glomme et al. [117] may have had more adsorption than even in [118]. The former group used plastic UniPrep 
filter vials: “Even with the UniPrep filters, a loss of drug can sometimes occur through adsorption on the filter 
membrane. For that reason, the first drops of the filtrate should be discarded.” 
Combining Centrifugation with Filtration 
It is potentially a faulty procedure, when separating solid from solution: to centrifuge the suspension first 
and then subject the centrifugate to a further filtration step. The reason is very simple: once the solid is 
removed, a “just-saturated” solution has no capacity to re-establish equilibrium when exposed to the surface 
of a filter, where adsorption usually takes place to some extent, and can account for a large fraction of the 
mass of a practically-insoluble compound. 
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Table 2. Potential sample loss due to adsorption in multiple transfers 
Drug logS0
a
 SD logS0
b
 SD
c
 Lit. Refs. 
Albendazole -6.01 0.05 -5.65 0.15 [119, 120] 
Carvedilol -6.15 0.03 -5.32 0.50 [48, 121-124] 
Cinnarizine -7.73 0.04 -7.14 0.28 [27, 125,126] 
Danazol -7.44 0.34 -6.02 0.28 [117,125,127-130] 
Felodipine -6.56 0.03 -5.77 0.10 [117,131,132] 
Glimepiride -7.90 0.10 -6.85 0.36 [133-135] 
Itraconazole -8.48 0.61 -9.67 -- d [117] 
Rimonabant -7.02 0.06 -6.35 -- d [136] 
Tamoxifen -8.54 0.15 -7.54 0.72 [137-140] 
Terfenadine -7.94 0.27 -6.99 1.05 [2,21,110, 141-147] 
Tolfenamic Acid -7.87 0.05 -6.16 -- d [137] 
Troglitazone -7.80 0.43 -5.34 0.78 [148,149] 
a
 Solid separated from slurry by two centrifugations [118]. 
b
 Averaged for the corresponding drugs from other published sources; values transformed to 25 °C before averaging. 
c
 Interlaboratory standard deviations, with references in the last column. 
d
 Single source comparison. 
 
Filtration 
Solubility suspensions which fail to clarify or sediment, must be filtered through membrane or glass filter. 
Filtration should not be done right after stirring, since the formation of a supersaturated solution upon 
intensive agitation may lead to an overestimated solubility. Since majority of compounds are inclined to 
supersaturation, it is recommended to allow the sample standing after stirring (as done in the sedimentation 
technique) to avoid this problem. Another source of error using filtration is the possible adsorption of the solid 
to the filter material, as just described. This can be substantially reduced or eliminated by pre-saturating the 
filter and discarding the initial portions of filtrate. Less attention was devoted in the literature to the proper 
filter type selection. A recent study has revealed the significant role of hydrophilic or hydrophobic type of 
filters on the solubility results of ionizable molecules [150]. The selection of appropriate filter type requires 
some knowledge of the acid-base chemistry of the sample. For the filtration of the ionized form of the 
compound, hydrophobic filter can be recommended. For unionized drugs, the uncharged-form hydrophilic 
filter can be recommended. These suggestions can be supported by the solubility results of papaverine (pKa 
6.39) measured at three pH values in the Britton-Robinson (BR) buffer, using different type of filters (Table 3). 
A further aspect in the selection of the filter may be its diameter and pore size. The most frequently used 
ideal membrane filter parameters are 25 mm diameter and 0.22 µm or 0.45 µm pore size. These pore sizes are 
suitable for macrocrystals and micronized particles, however nano-size solids require specific filters. The 
solution should be slowly filtered in small 300-600 µL portions. The first 1-5 aliquots saturate the filter, and 
thus need to be discarded, while the sixth aliquot can be used for concentration measurement. 
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Figure 19. The comparison of the intrinsic solubility values of twelve practically-insoluble drugs [118] to the 
corresponding averaged values taken from other published studies (with values transformed to 25 °C [26]). 
Notably, the logS0 values along the horizontal axis are 1-3 (or more) log units lower than the average values 
reported from other published, with the exception of that of itraconazole. See text.  
Table 3. Effect of separation method and filter type on the equilibrium solubility of papaverine  
Method of separation of 
solid from the saturated 
solution 
SpH (mg/mL) 
pH 2.80 
100% charged form 
pH 6.40 
50% charged 
50% uncharged form 
pH 9.55 
100% uncharged form 
Sedimentation 39.1 20.4 0.017 
Filtration on hydrophilic 
filter (PVDF) 36.3 22.4 0.016 
Filtration on 
hydrophobic filter 
(nylon) 
36.6 9.52 0.011 
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Solubility Units, Conversion Issues, Tabulation of Results and the Use of Logarithmic Plots  
Solubility measurements have been reported in many different concentration units: weight/volume (e.g., 
mg/mL, μg/mL), mol/L (molarity, M), mol/kg (molality, m), mole fraction, and mass fraction – just to name a 
few [4]. Mole fraction, mass fraction, and molality units are popular choices when solubility is determined over 
a wide range of temperatures, since the units do not depend on the density of the solutions in aqueous 
solutions. Also, such units are convenient to use with viscous solutions [151]. When solubility is reported in 
“practical” mg/mL or μg/mL units, the equivalent molecular weight needs to be clearly indicated (e.g., 
“concentration is expressed as free base equivalents,” meaning that it is the molecular weight of the free base 
that is to be used to convert practical units to molarity units).  
As different units are in common usage, it is too easy to make a mistake in converting the units to the 
common molarity scale. Solubility should be presented in log units (preferably based on molarity), since 
(a) direct values span over many orders of magnitude and cannot be accurately depicted in S-pH plots at the 
low end of the scale, and (b) since errors in log values do not depend on the magnitude of the log solubility. 
When molality units are used, it would be useful if the actual solution density is reported at the various 
temperatures studied. 
 
 
Conclusions 
This commentary drew on the extensive experimental knowledge and experiences of several laboratories 
with which the authors are associated. Reviewed were a number of factors that can affect the quality of 
equilibrium solubility measurement as a function of pH of druglike molecules, especially those which are only 
sparingly soluble. It was concluded that the traditional shake-flask and the potentiometric CheqSol methods 
Recommendations for phase separation 
Sedimentation is recommended as the safest method for separation of the solid from the saturated 
solution. For non-clarifying, opalescent colloid solutions the centrifugation can be used.  
If filtration cannot be avoided, then it is essential that the proper filter type is selected. For polar, 
ionized species hydrophobic (nylon) is recommended, while for unionized species the hydrophilic type 
filters (PVDF, PES) are recommended. The filtration should be done after sedimentation (resting time), and 
not directly after agitation. Pre-saturation of the filter is necessary. The initial portions of filtrate should be 
discarded. 
Recommendation for Reporting Solubility Units  
It is recommended that solubility be tabulated both in molarity and in practical (mg/mL) units, as done 
in the Handbook of Aqueous Solubility Data (Yalkowsky et al. [152]). Standard deviations in the measured 
solubility (based on averaging three or more values) should be included in the table of values. Additionally, 
a graphical display of logS vs. pH (but not S vs. pH) would be helpful.   
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could be used, provided that proper assay protocol is followed. It was stressed that independently-determined 
pKa values of the drug be used in the analysis of the logS-pH data. The importance of solid state 
characterization was also stressed, citing several case studies of polymorphic and cocrystal transformations. 
The complexity on the solution side of solubility-pH measurement was illustrated with several case studies, 
where aggregates (micellar and sub-micellar) and drug-buffer or drug-coformer complexes appeared to form. 
The importance of measuring pH accurately in buffered and unbuffered solutions was discussed at length. 
Methods and pitfalls of separating solid from saturated solutions were critically discussed. The proper 
reporting of the temperature, ionic strength, buffer capacity, and other experimental detail was encouraged. 
When such “good practices” could be followed, it is expected that high quality results in solubility 
measurement could be achieved. 
 
Glossary   
API active pharmaceutical ingredient 
Bjerrum plot Average number of ionizable protons, n̄H, bound to a weak acid/base, plotted as a function of 
pH. For example, for a monoprotic acidic drug with a pKa 4.5, n̄H = 1.0 at pH 2, n̄H = 0.5 at pH 4.5, 
and n̄H = 0.0 at pH 9 [27, 153]. 
BR Britton-Robinson buffer [154] 
CCDC Cambridge Crystallographic Data Centre 
CheqSol Chasing Equilibrium Solubility 
CMC critical micelle concentration 
CSC critical stabilization concentration 
CSD Cambridge Structural Database 
CV coefficient of variation 
DTT Dissolution Titration Template (potentiometric method to determine intrinsic solubility, S0) 
DSC differential scanning calorimetry 
DASH Interactive package from the Cambridge Crystallographic Data Centre (CCDC) for solving crystal 
structures from powder diffraction data (https://www.ccdc.cam.ac.uk/solutions/csd-
materials/components/dash/) 
GSAS General Structure Analysis System. Comprehensive system created by Allen C. Larson and 
Robert B. Von Dreele of Los Alamos National Laboratory for the refinement of structural 
models (http://www.ncnr.nist.gov/xtal/software/downloads.html), for both X-ray and neutron 
diffraction data  
HH Henderson-Hasselbalch equation (e.g., Eq. 1) 
I ionic strength of the solution 
IR infrared spectroscopy 
Kn aggregation constant, where n is the degree of aggregation  
Ksp drug-salt or drug-coformer (cocrystal) solubility product 
LJP liquid junction potential 
LLPS liquid-liquid phase separation 
MUB Minimalist Universal Buffer 
MSZ Metastable Zone 
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[PC]
2
 Potentiometric Cycling for Polymorph Creation 
pKa negative logarithm of the ionization constant 
pKa
Gibbs
 pH where the drug in the uncharged form co-precipitates with the drug in the salt form 
pHsat equilibrium pH of a saturated solution 
PXRD powder X-ray diffraction characterization of the solid form  
S solubility, ideally expressed in units of mol/L (M), μg/mL, or mg/mL  
S0 “intrinsic” solubility (i.e., the solubility of the uncharged form of the compound) 
Sw “water” solubility, defined by dissolving enough pure free acid/base in distilled water (or water 
containing an inert salt – as ionic strength adjustor) to form a saturated solution. The final pH of 
the suspension, pHsat, and S0 can be calculated by the HH equation (when valid), provided the 
true pKa is known. Compound added as a salt form may disproportionate into free acid/base, 
depending on how much solid had been added. It is not generally possible to calculate the pH 
and S0 of such a drug salt suspension.   
SpH “pH buffer” solubility (i.e., the total solubility of the compound at a well-defined pHsat) 
TGA thermogravimetric analysis 
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Appendix A – Buffer Capacity and Ionic Strength – Too Little, Too Much, or Just About Right 
Many buffer formulations have been described in the literature. Very useful detailed descriptions of 
specialty buffers have been tabulated by Perrin and Dempsey [155]. In this Appendix, five examples of buffer 
solutions are described, with emphasis on use in solubility measurements. 
Unbuffered Water 
Figure A1a shows the buffer capacity and ionic strength distribution as a function of pH for the “blank” 
titration shown in Figure A2a. 
 
  
 
 
  
Figure A1. Plots of the buffer capacity and ionic strength as a function of pH for the unbuffered “blank” (a) 
solution, for the common phosphate buffer (b), and for four “universal” buffer solutions (c-f). 
This is a case of the least buffered aqueous solution possible, where trace level of buffering is solely 
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provided by the ionization of pure water. The region between pH 4 and 10 is characterized by buffer capacity < 
0.005 mM/pH and ionic strength < 0.0005 M. The commercial pKa analyzer dispensers adding minimum 
volumes of 0.5 M HCl or NaOH would not be able to resolve pH points any better than about 2 pH units in the 
vicinity of pH 7. This case may be simply called the “unbuffered” solution. 
USP 50 mM Phosphate Buffer 
Figure A1b shows the buffer capacity and ionic strength distribution as a function of pH for the extended 
version of the popular 50 mM phosphate buffer defined in U.S. Pharmacopeia – National Formulary No. 25 
[156]. A characteristic feature is the high buffering occurring near pH 6.8 (27.4 mM/pH), as shown in the 
figure. Buffer capacity becomes minimal around pH 4.4 (1.0 mM/pH) and 9.3 (0.7 mM/pH). This is just about 
enough capacity for commercial pKa analyzers to adjust the pH of the phosphate solutions using typical 
titrants. Although the average ionic strength is near 0.1 M, the value increases from 0.05 M to 0.14 M as pH is 
adjusted across the pH 6.8 region, as indicated in Figure A1b. Compensation for this level of change in ionic 
strength is theoretically feasible [22]. The phosphate buffer is suitable for most applications in solubility 
measurement. But one could do better.  
McIlvaine Universal Buffer 
The McIlvaine universal buffer [157] is sometimes used in dissolution studies as a function of pH. It is 
formulated by adding different mixtures of 100 mM citric acid (3-98 mM) and 200 mM Na2HPO4 (4-195 mM), 
to cover the pH range from 2 to 8. The buffer mixture has high buffer capacity, to be sure. Its unfavorable 
property vis-à-vis solubility measurement is that ionic strength varies from near zero to 0.5 M, as can be seen 
in Figure A1c. Also, the very high and continuously-variable phosphate concentration does not make this a 
suitable buffer for studying sparingly-soluble basic drugs, since analysis of drug-phosphate salt precipitates 
could be unwieldy [24]. In some cases the McIlvaine buffer could be useful for studying acidic drugs. But there 
are better choices. 
Britton-Robinson Universal Buffer 
A very well formulated universal buffer is that of Britton-Robinson [153]. It consists of equimolar (e.g., 
40 mM) mixtures of acetic acid, phosphoric acid, and boric acid [22, 45] Since the initial pH about 1.9, 
adjustment of the buffer with NaOH titrant can set the pH over a wide range. As Figure A1d shows, the buffer 
capacity is evened out to an average value of 14.8 mM/pH in the pH interval from 3 to 11, which is a 
considerable improvement over the simple phosphate buffer (Figure A1b). When mass spectrometry is used 
to measure concentrations, the present of phosphate is problematic. Also, if the sample contains 1,2-diol 
groups, the boric acid may form covalent bonds with them. It can be noted that the ionic strength increases 
ten-fold uniformly as the pH increase from 2 to 11 (0.02 to 0.2 M), which should not be a problem in data 
analysis [22]. Generally, the Britton-Robinson buffer can be highly recommended, provided it is compatible 
with the detection method and the chemistry of the sample.  
Minimalist Universal Buffer (MUB) 
Finding ways to avoid the chloride may be a good feature when studying weaker salt formers of drugs. In 
cases where chloride, borate, and phosphate need to be avoided, the “AEM-10.10.30” (devised here) may be a 
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suitable universal buffer (Figure A1e). The AEM buffer consists of 10 mM acetic acid, 10 mM ethylenediamine, 
and 30 mM mesylic acid, which is used to adjust the starting pH to about 1.7. The buffer capacity is nearly as 
uniformly distributed as in the case of the Britton-Robinson buffer, but a lower level is chosen (average of 4.4 
mM/pH over pH 3-11). This buffer capacity would allow the commercial pKa analyzers to easily set pH in 
increments of 0.2 across the pH range, using 0.5 M titrants. In that sense, the concentrations of buffer 
components are “minimalist” – being just right for the titration equipment used. Because the universal buffer 
is a combination of an acid and a base, the ionic strength remains nearly constant across the working pH range, 
which is unique among the common universal buffers, and is particularly well suited for solubility applications. 
A buffer similar to the AEM, consisting of lactic acid and ethylenediamine, has been successfully tested [114].  
As oil, ethylenediamine may not be convenient to work with. To remain chloride-free, alternatively, it may 
be useful to form a dimesylate or diacetate salt from ethylenediamine free base and either mesylic or 
trifluroacetic acid. 
Mass Spectrometry-Friendly Minimalist Universal Buffer (MS-MUB) 
In the AEM-10.10.30 buffer design, mesylic acid is proposed to set the initial pH to 1.7. However, mesylic 
acid is not compatible with mass spectrometer use. AET-25.25.75 (25 mM acetic acid, 25 mM 
ethylenediamine, 75 mM trifluroacetic acid) was formulated to be MS-friendly, higher-capacity version of the 
AEM buffer. Figure A1f shows the buffer capacity and ionic strength as a function of pH capacity, with average 
values of 8.3 mM/pH and 0.096 M, respectively. Excessive dilution effects due to titrant addition would not 
favor higher buffer capacity versions. 
Titration Curves and the Incrementing of pH by Titrant Additions 
Figures A2 show the titration curves for four of the above cases. Figure A2a shows that the pH adjustment 
across the steep pH 3-11 region in the “blank” titration would be difficult to achieve with normal titration 
equipment and titrant concentrations, if 0.2 pH increments were desired. By selecting the 50 mM phosphate 
buffer, the steepness in the working pH range is lessened, and it should be possible to control pH adjustment 
with the usual equipment. It gets much easier with the virtually linear titration curve produced with the 
Britton-Robinson universal buffer (Figure A2c). The linearized titration curve in Figure A2d for the minimalist 
universal buffer, AEM-10.10.30, is nearly as attractive as that of the Britton-Robinson buffer. AET-25.25.75 
looks similar to the AEM buffer. 
Possible Uses of the Minimalist Universal Buffer 
Figure A3 shows the expected titration curve for haloperidol (free base) in AEM-10.10.30 buffer, titrated 
with 0.5 M mesylic acid (cf., Figure 3a). Haloperidol itself provides good buffering below pH 5. Above pH 5, the 
titration curve would have been too steep, were it not for the buffering action of the AEM buffer. The region 
from pH 5 to 12 is sufficiently buffered, so that pH increments of 0.2 could be achieved by 0.5 M titrant 
minimum volume additions. This is an example of a “minimalist” buffer, which provides a boost where needed, 
but otherwise stays minimally intrusive. 
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Figure A2. Titration curves for four of the examples in Figure A1. See text. 
 
  
Figure A3. Examples of titrations of haloperidol in the AEM minimalist buffer at two different concentrations of 
buffer components. 
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Appendix B – Simple Henderson-Hasselbalch Equations 
The relationship between solubility and pH can be easily derived for a given equilibrium model. For 
example, in the case of a simple monoprotic base, a saturated solution can be defined by two equations and 
the corresponding constants: 
 
  BH+  H+ + B     Ka = [H
+][B] / [BH+]          (B.1a) 
  B(s)  B      S0 = [B]             (B.1b)  
S0 is the intrinsic solubility (of the free base at pH >> pKa). At a particular pH, solubility is defined as the 
mass balance sum of the concentrations of all of the species dissolved in the aqueous phase: 
 
  S = [BH
+
] + [B]                   (B.2) 
The square brackets denote molar concentration of species (at the constant ionic medium reference state 
[27]). The above equation is usually converted into an expression containing only constants and [H
+
] (as the 
sole variable), by substituting the ionization and solubility Eqs. B.1 into Eq. B.2. 
  
  S = [H+][B] / Ka + [B] 
     = So ( [H
+]/Ka + 1 )         
       = S0 ( 10 
pKa - pH + 1 )                 (B.3) 
 logS  =  logSo + log(10
+pKa - pH + 1 )               (B.4) 
The dashed curve in Figure 1a is a plot of Eq. B.4 for atenolol (pKa 9.54). At the bend in the curve, the pH 
equals the pKa. For pH >> pKa, the equation represents a horizontal line: logS  logSo; for pH << pKa, the 
equation is a diagonal line with slope -1. 
Other cases may be similarly derived. Table B.1 is a collection of solubility equations for such simple cases, 
with up to two pKa values. 
Table B.1. Solubility-pH Equations for Mono- and Diprotic Molecules 
Type Equilibrium Intrinsic Solubility Equation 
Monoprotic Acid 
    S0 
HA(s)      HA logS = logS0 + log{10
–pKa + pH
 + 1 } 
Diprotic Acid 
   S0 
H2A(s)   H2A 
 
logS = logS0 + log{10
–pKa1 –pKa2 + 2 pH
 + 10
–pKa1 + pH
 + 1} 
Monoprotic Base 
   S0 
B(s)     B logS = logS0 + log{10
+pKa – pH
 + 1 } 
Diprotic Base 
   S0 
B(s)     B logS = logS0 + log{10
+pKa1 + pKa2 – 2 pH
 + 10
+pKa2 – pH
 + 1} 
Diprotic Ampholyte 
   S0 
HX(s)      HX logS = logS0 + log{10
+pKa1 – pH
 + 10
–pKa2 + pH
 + 1} 
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Appendix C – The Four-Parameter Electrode Calibration Procedure  
In highly-developed potentiometric methods for pKa determination, research-grade combination pH 
electrodes are calibrated to cope with large swings in ionic strength, over a wide range of pH 0.5-13.5 [27]. 
Some of the calibration procedures can be translated to pH reading in solubility–pH experiments. The voltage 
read by a pH meter needs to be converted to ‘pH’ on what is called the operational scale. In the two-part 
procedures of the Pion Inc and Sirius Analytical Ltd pKa analyzers, the pH electrode is first ‘calibrated’ before 
each assay with a single aqueous pH 7.00 buffer(traceable to the NIST phosphate buffer at 25 °C, pH 6.865 
[155]), with the ideal Nernst slope assumed to be 59.16 mV/pH (25 °C). Then this operational pH is 
‘standardized’ to a concentration-based pcH scale (i.e., -log[H
+
]), done on a weekly basis. Both steps are carried 
out under thermostated conditions (most commonly at 25 ± 0.1 °C). 
Equilibrium quotients in currently practiced pKa and solubility procedures employ the constant ionic 
medium activity scale where pcH rather than pH is applied. This is a valid thermodynamic activity scale, where 
the limiting state is the ionic strength-adjusted solution (e.g., 0.15 M KCl), rather than pure water. For many 
years, the pH–to–pcH standardization has been based on the equation below [27, 45, 111-113],  
 
 pH = α + ks ∙ pcH + jH ∙ [H
+] + jOH ∙ Kw/[H
+]             (C.1) 
 
where Kw is the ionization constant of water, Kw = [H
+
][OH
–
] (concentration scale, molarity). At 25
 
°C and 0.15 
M ionic strength, pKw = 13.764. The four parameters (α, ks, jH, jOH) are determined by a weighted least-squares 
procedure using data from alkalimetric “blank” titrations of known concentrations of HCl [45]. Typical aqueous 
values of the adjustable parameters are shown in Table C.1. Such a standardization scheme extends the range 
of accurate pH measurements and allows pKa values to be assessed as low as 0.6 (caffeine) and as high as 13.3 
(salicylic acid) [27]. 
Table C.1 Typical four parameter electrode standardization parameters
a 
Temperature 
(°C) 
Ionic Strength 
(M) 
α kS jH jOH 
25 0.00 0.070 0.9971 0.8 -0.6 
25 0.15 0.090 1.0019 0.5 -0.5 
25 1.00 0.109 0.9935 -1.2 0.0 
37 0.00 0.070 0.9972 0.3 -0.8 
37 0.15 0.091 1.0017 0.0 -0.7 
37 1.00 0.109 0.9933 -2.7 0.2 
a 
Each pH electrode may have its own distinct parameters, which need to be checked on a weekly basis during periods of 
active use [27]. 
The intercept constant, α, is ideally defined by -logfH, where fH is the activity coefficient of the H
+ (i.e., 
activity of H+, {H+} = 0.81 [H+]). In practice, α may also serve to mop up other effects not dependent on pH. The 
slope factor, kS, is used to take into account that a particular pH electrode may not have the ideal 100% 
Nernstian slope. Liquid junction potentials that form in very low ionic strength solutions can be slightly 
pH-dependent, an effect that propagates into the kS empirical slope factor parameter [27]. The jH term corrects 
pH readings for the nonlinear pH response due to the liquid junction and asymmetry potentials in acidic 
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solutions (pH<2.5). The jOH term corrects for alkaline (pH>11.5) nonlinear effects, due to liquid junction 
potentials. The latter parameter may also compensate for ‘sodium error’ when NaCl is used to adjust the ionic 
strength and/or when NaOH is the titrant.  
In a typical “blank” titration procedure to determine the four parameters, about 0.9 mL of 0.5 M HCl is 
added to 20 mL of 0.15 M NaCl (or KCl), to lower the pH to 1.8. The solution is then carefully titrated with 
standardized 0.5 M NaOH (or KOH) up to about pH 12.2 (which consumes about 2.0 mL of the titrant). 
Figure A2a shows such a plot. Since the ionization constant of water is known over a wide range of conditions 
[158] and since the concentrations of NaOH and HCl in the titrated solution are also precisely known at each 
point, then the hydrogen ion concentration, [H
+
], can be calculated, so that at each point in the titration, both 
the operational pH and the concentration pcH are known. The parametric relationship between the two scales 
can be deduced by least-squares fitting of the calculated pcH titration curve to the observed pH titration data 
points. The typical values shown in Table C.1 (e.g., for 25 °C, I = 0.15 M) can vary substantially from electrode 
to electrode: α = 0.08-0.15, kS = 0.995-1.005, jH = 0.5-1.0 or higher, and jOH = -0.5 or lower. For a given 
electrode the precision of the four parameters are typically ±0.02, ±0.002, ±0.2, and ±0.4, respectively. 
When the differences pH - pcH in blank titrations are examined as a function of pH, the variance in the 
interval pH 4-9 can be very large, as is expected of the unbuffered neutral pH region. Regression determination 
of the four parameters to such data requires an appropriate weighting scheme [159]. 
Besides the determination of the four parameters, the blank titration quality controls two other 
experimental variables. (a) The volume of standardized NaOH needed to neutralize the added HCl determines 
the HCl concentration very precisely. (b) CO2 concentration in the 0.15 M KCl and in the NaOH titrant can be 
precisely determined, since the neutral pH region clearly reveals the pKa profile of carbonic acid. 
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Appendix D - Questionnaire Summary 
 
Ten Participants from:                          _6__ industry   _4__academia      _0__regulatory agency  _0__other 
Doing solubility meausurements:  _8__ regularly  _1__occasionally  _1__never 
Attended panel discussion:       _9__ yes        _1__no 
In various topic areas (italics below), statements were posed (underlined below), and the participants were 
asked if they agreed (YES), disagreed (NO), or were unsure (?) regarding the statement. The counts of 
responses are indicated in brackets at the beginning of the statement. Additional comments are in quotation 
marks and highlighted in yellow. 
 
Solubility Units, Tabulation of Results and the Use of Logarithmic Plots  
 
[9YES, 1NO] Solubility needs to be tabulated both in molarity and in practical (mg/mL or μg/mL) units. 
Logarithm should be expressed in molar concentrations. 
“Molarity scale is more appropriate for me as a chemist. MW should be indicated together with molar solubility.” 
“I would not recommend to use S in μg/mL and logS in molar unit. As for me I would always use the molar concentration 
for the solubility measures. It would force people to characterize the solid form (salt? Not salt, partial) a bit more 
rigorously. In the worst case scenario we should express solubility in both units!” 
 
[7YES, 3NO] Standard deviations in measured solubility (based on averaging 3 or more values) should be 
presented.  
 
[9YES, 1NO] Additionally, a graphical display of logS vs. pH (but not S vs. pH – unless tabulated numbers are 
also available) would be visually helpful.   
 
Solubility Methodology and the Benefits of Knowing the Accurate pKa 
 
[10YES] The “gold standard” multiple-pH buffer shake-flask measurement is recommended for challenging 
ionizable molecules. 
“[I would agree] as long as “shake-flask” is broadly understood – in situ UV concentration monitoring, for example, is a 
“shake-flask” measurement of sort.” 
 
Which other methods may also be satisfactory (with the Henderson-Hasselbalch relationship independently 
validated):   
[3 CheqSol; 2 potentiometry; 1 direct microscopic obs. of drop; 1 PXRD; 1 dissolution calorimetry]  
 
[10YES] Miniaturization (0.2 – 2 mL) can be recommended, as long as the protocols are rigorous and well 
validated.  
 
[10YES] For ionizable molecules, the measurement of Sw without measuring the equilibrium pH is not 
Alex Avdeef et al.             ADMET & DMPK 4(2) (2016) 117-178 
170  
recommended.   
“Water solubility may be of practical interest, but it must be complemented, not substitute the procedure described 
above.” 
 
[10YES] It is far better to measure SpH values in well-qualified buffers, at 3 or more equilibrated pH values, 
symmetrically bracketing the pKa. 
 
[8YES, 2NO] The logS – pH data should be evaluated to estimate the value of the intrinsic solubility, S0. 
 
[10YES] Solubility is a function of temperature, so the actual assay temperature needs to be reported. 
“Measurements at multiple temperatures are highly desirable, since they may indicate also at important changes in the 
dissolution mechanism.” 
“Graphs vs. T are also helpful.” 
 
[6YES, 4?] If solubility is measured at several different temperatures, it is normal to report solubility in either 
mole fraction (x2) or molality (mol/kg solvent) units. It would be very helpful also to include the solubility in 
molarity units (mol/L solution).  
“We think it is better to provide Molar solubility always, indicating the temperature of each measurement.”  
 
[10YES] Measured solubility can be affected by ionic strength (particularly when salt solubility is measured), so 
the ionic strength usually needs to be reported. It is easy to calculate the ionic strength coming from the 
buffers and the adjustors, but it is not evident how to contemplate the contribution of the own sample. 
 
Equilibration Time and Stirring Protocol 
 
[9YES, 1?] Ordinarily, the shake-flask method determines the equilibrium solubility of the most stable solid 
state form of the compound (which may be different from the original solid form added to the suspension).  
“I am not sure about ‘the most stable form,’ but the two forms may immensely differ.” 
“It is recommended to prove this by alternative method, DSC, or PXRD.” 
“It would be beneficial to confirm the solid state after solubility measurements especially if the measurement relies on  
precipitation.” 
 
[6YES, 3NO, 1?] Probably 24 h is a good average equilibration time for the uncharged drug form equilibration, 
but when measuring the equilibrium solubility of practically-insoluble drugs it is a good idea to test longer 
times (e.g., 48–72 h). In regions of pH where the sample molecule is predominantly ionized (e.g., salt solubility 
applications), equilibration times as short as 1-6 h may be adequate. 
“pH control is a good tool to see if equilibrium has been reached.” 
“It is helpful to have measurement during the incubation time.” 
 
[5YES, 3NO, 2?] The 25% stir + 75% sedimentation timing protocol (Baka et al. J. Pharm. Biomed. Anal. 2008, 
46, 335-341) is recommended. Stopping the stirring and allowing the solid to sediment contributes to 
formation of better quality crystals, consistent with a truly equilibrated solution.   
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“It could be a different ratio.” 
 
[5YES, 3?, 2NO] In regions of pH near the pKa
Gibbs (sometimes called ‘pHmax’), where the salt form plus the 
uncharged form of the drug co-precipitate (e.g., Serajuddin and Rosoff 1984; Serajuddin and Jarowski 1984, 
1985, 1993), longer equilibration times (e.g., 24 ]-48 h) may be necessary due to the tendency of the solutions 
becoming supersaturated.   
 
[3YES, 4?, 3NO] For some kinds of drug (e.g, phenothiazines), at temperatures above the Krafft point, the solid 
may dissolve directly into a micellar or a highly supersaturated form, which may, in turn, transition into an oil 
(depending on pH), longer equilibration times (e.g., 48-72 h) may be necessary if equilibrium solubility is to be 
measured.   
“These kinds of compounds may go through liquid-liquid phase separation and additional equilibration time will not lead to 
solid form precipitation.“  
 
[3YES, 3?, 4NO] Equilibration times as long as many days have been used. Ordinarily, long times are not 
recommended, unless one is interested to determine the solubility enhancement of a biorelevant medium or 
human intestinal fluid. 
“Long times can be helpful to follow re-crystallization of alternative solid forms.” 
“Equil. time should be as long as necessary to provide precipitation of the most stable polymorph.” 
 
Shortening the Equilibration Time 
 
[2YES, 3?, 5NO] If the initial solid form of the drug is unknown, dissolve the crystals in the assay vial with a 
drop or two of methanol (or another volatile organic solvent in which the crystals dissolve). Swirl the vial to let 
the methanol evaporate before adding the solution medium. Usually the freshly-formed crystals wet better 
and dissolve quickly. This procedure is often used in the DTT method. 
“The choice of solvent depends on the substance.” 
“Suitable for selection study of only candidate.” 
 
[4YES, 3?, 3NO] If the initial solid form of the drug is unknown, add the crystals to the buffer solution. For a 
weak acid/base drug, add a known amount of standardized base/acid titrant to dissolve the solid, but avoid 
extremes of pH. Quickly add a known amount of standardized counter titrant to the desired starting pH. A 
procedure like this is used in the CheqSol method, with repeated cycles of dissolution and re-precipitation by 
pH adjustment.   
“Method suitable for fast solubility determination.” 
 
[2YES,5?,3NO] The Loftsson et al. (Int. J. Pharm. 2005, 302, 18–28) temperature spiking cycles and seed crystal 
may be used to shorten the equilibration time.  
“Careful analysis of the solid phase and microscopy observations are needed for correct interpretation of results.”  
 
[1YES, 6?, 3NO] The Facilitated Dissolution Method of Higuchi (cf., Avdeef [4]), consisting of adding a drop of 
water-immiscible oil to the solution medium, may be used to speed up the rate of equilibration. The method is 
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fundamentally rigorous and deserved much more attention than it has received, including validation studies.  
“This is an interesting approach that have not been much appreciated. We’d love to try it out.” 
 
[1YES, 8?, 1NO] Most of the above methods look promising. 
 
Solution and Solid State Composition  
 
[9YES, 1NO] It is a good idea to keep the assay solutions simple and to define all components precisely. Report 
the state of the solid, if known (e.g., polymorphic, hydrate, solvate, amorphous, stereoisomer). 
“It is a must to characterize the solid samples as detailed as possible (structure, meso-structure, particle size, shape, 
surface area, etc.), also in the process of dissolution recrystallization.” 
“Time and resource consuming. Not be used for selection.” 
 
[10YES] When possible, it is a good idea to do solid state characterization of the precipitate at the end of 
equilibration, to determine if a solid-state transformation had taken place, or to confirm the crystalline nature 
of the solid, or to ensure that a mixture of solid forms is not present.  
“At the beginning, at the end, at the intermediate stages; “unusual” temperature dependence of solubility also suggests a 
change in the solid form.” 
 
[10YES] When studying salt solubility, it is particularly helpful (and sometimes necessary) to specify the actual 
weight of sample in each vial. (It can be unhelpful to see statements such as “excess solid was added.”) 
“Actual weight should always be specified.” 
 
[9YES, 1NO] It is not enough to state that “water was used” as the solvent. Was there any added ionic strength 
adjustor (e.g., 0.15 M NaCl, etc.)? Was carbon dioxide purged out? Low soluble bases such as terfenadine can 
indicate solubility over several magnitudes due to the effect of ambient CO2 in unbuffered solutions. 
“All details of the method, procedure, have to be described.” 
 
pH Measurement Using Glass Electrodes 
 
[10YES] It is highly recommended that the final pH of the saturated solution be carefully measured, using a 
properly standardized electrodes. (It is a risky practice to assume that the assay buffer pH is not altered by the 
addition of sample.) 
“Besides final pH, value of the beginning and, for example, after stirring, should be indicated.” 
 
[10YES] Particular attention should be given to the pH electrode calibration, especially when extreme pH is 
measured (pH<1 or pH>12) or when the ionic strength reaches high values, as in the case of salt solubility 
measurement. 
 
[7YES,3?] State whether the reported pH is on the “operational” or the “concentration” scale. The “mixed” 
scale is not recommended. 
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“The definition of operational pH and mixed pH scales should be provided. If mixed scale refers to the measurement of H
+
 
in activities and the rest of species in concentrations, we don’t see why the mixed scale is not recommended if everything is  
well specified.” 
“Operational [is preferred].” 
 
[6YES, 4?] A strong case can be made that general solubility equilibrium quotients are best formulated in the 
concentration scale (rather than activity), with pH electrodes standardized in a constant ionic medium, e.g., 
0.15 M NaCl. This may be especially important when salt solubility measurements are performed.  
“We have never done that, but can be a good idea.“ 
 
[8YES, 1?, 1NO] State how pH was adjusted (e.g., 0.1 M HCl, 1 M NaOH, etc.). Statements like: “concentrated 
H3PO4 was added drop-wise to adjust the pH” are not clear enough. It is far better to state the precise 
concentration and volume of the titrant used to adjust the pH to the desired starting point. 
“We agree with the comment. “ 
  
Buffers 
 
[10YES] It is inadequate to state that “buffers were used”. State precisely which buffer compounds were used. 
Problems with specific buffers can occur so it is important to specify the nature.  
 
[10YES] State which salt forms of buffers were used (e.g., KH2PO4, Na2HPO4.2 H2O).   
 
[9YES, 1NO] State the concentrations of the buffers, since this will be needed to calculate the total ionic 
strength. Ordinarily, relatively low buffer concentrations (e.g., 5-10 mM) can be recommended.  
“10 mM is not enough to buffer solutions of compounds with relatively high solubility” 
 
[6YES, 3?, 1NO] Some buffers have inappropriately high UV absorptivity, if concentration is determined by UV 
spectroscopy. List some examples of buffers to avoid.   
“We normally use HPLC for compound quantification.” 
“HEPES, phosphate buffer(s) [are to be avoided] if [sample] substance absorbs below 240-250 nm.” 
  
Separating Solid from Saturated Solution 
 
[7YES, 2?, 1NO] Filtration is recommended, using hydrophilic filters, typically 0.2-0.45 μm pore sizes. 
“As Krisztina said, it depends on the pKa of the compound and also its log P.” 
“Type of filters may influence the So value; maybe several types of filters should be used (depending on the pKa value and 
pH of solution).” 
“Filtration is very time consuming and for industry it is preferred to do centrifugation. We have performed centrifugation  
for a 5 or 6 years and no problem was encountered yet. Perhaps some micellar problems were encountered but the 
detection of this is not always clear. A better way to find those problems could be advisable.” 
[8YES, 2?] It is useful to discard the first 10-25% filtered solution, to allow filters and vial surfaces to be 
saturated with adsorbed compound. The filtration step should not be rushed.  
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“One must take care that no change in the solid form occurs during filtering (possible for highly polymorphic [prone] 
solids).” 
[6YES, 3?, 1NO] If colloidal dispersions or “promiscuous inhibitors” (McGovern et al. J. Med. Chem. 2002, 45, 
1712-1722) are suspected, then the filtered solutions may be further subjected to ultracentrifugation. 
 
[7YES, 2?, 1NO] It is highly inadvisable to centrifuge first and then filter. 
 
Additional Comments/Suggestions 
 
“A mass spectrometer can be very helpful in cases of low sensitivity of other techniques or to corroborate the presence of 
aggregates, etc.” 
 “Intrinsic solubility is not always important; need to know solubility at certain pH without using pKa for back-calculation.” 
“Generally: my early-research group analyzes 15,000 cpds/annum in a high throughput type assay (initial dissolution in 
DMSO followed by addition to aqueous buffer, 24 h shaking, filtration, HPLC) and approximately 1000 cpds/annum in a 
shake flask assay (solid compound + buffer or formulary solvents/various pHs), 24 h stirring, centrifugation, HPLC). Many of 
the suggestions given in the questionnaire are very interesting but definitely not feasible in an industry lab which has to 
provide the researcher with data as fast as possible and as accurately as necessary. Early solubility data very often serve as 
estimation for the pharmacologist and as comparison of different clusters within HT Lab. They don’t need exact numbers 
but rather a hint if the compound could have an solubility issue during further activities.” 
 “I am responsible for the PhysChem Lab in the Medicinal Chemistry – Global Drug Discovery. We have to measure the 
solubility of about 12,000 new compounds every year to support our colleagues in the different projects. They don’t need 
absolutely exact solubility results at this time of research; they need the results very fast for a ranking between the several 
compounds. Thus some of the ideas and questions below are very good from the scientific point of view but not feasible for 
our high throughput measurements. In such cases I put a star (*) in the space following the statement.” 
“It would be very helpful to have two kind of operational suggestions: (1) a quick ones for a more routine work; (2) a more 
complete suggestions to be applied when compound is already in candidate profiling. Quick results must be obtained at 
the physchem departments in the lead optimization phase while in the candidate profiling more time and compound 
amount can be devoted to study the solubility of the compound.” 
“Although we are measuring HT solubility in a pragmatic way (DMSO 5% precipitative solubility), [such measurements] are 
still useful in drug discovery. We can select the most soluble series, we could even build some sort of in silico guide for 
chemists using half a million compounds’ solubility data (pH 7.4, 1 h equilibration 0.1 M phosphate buffer) expressed in 
molar term using the matched molecular pairs approach. So we have a long lists of substituents with the average 
contribution to solubility (enhance or reduce) and its standard deviations. The pharmaceutical industry is interested in 
measuring solubility in various bio-relevant media such as Simulated Lung Fluid, Simulated Intestinal fluid, etc. I think even 
for those measurements the pH, solid form characterization, temperature etc are important details to provide. Overall, it 
was an exciting session and I was amazed how many people were there until nearly midnight!” 
“Solubility measurement methodology depends on sample quantity availability, precision of measurement and 
characteristics of the drug molecule (purity, solid state properties).” 
“[Reporting] the amount of solid in excess is important, especially when the solid is a salt, as the counterion may affect pH 
of the solution significantly.” 
“Shaking intensity may be more important than time of incubation.” 
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“I do not like people saying "24 h" [incubation time]. We have reached equilibrium at 4 h in some cases. 
“I was really interested in learning yesterday on the importance of sedimentation on solubility measurements. If you have a 
relevant paper PLEASE could you send it to me?” 
“Buffer species identity: We have actually observed effects (Vertzoni et al. JPP, 2004) when the API (if ionized) interacts 
with the oppositely charged (?) species of the buffer system.” 
 
Extra Topic Questions - Describe How You Handle The Following Potential Challenges 
 
 poor wettability   
“High stirring power during a long time.” 
 adding a very small weight (e.g., 1 – 10 μg) of drug to a vial  
[No comments.] 
 formation of drug aggr./oligomers (dimers, trimers, …), micelles, or drug-buffer complexes   
“Shake-flask S-pH profiles” 
 formation of ion-pair between ionic str. adjustor (e.g., NaCl, etc.) and charged form of drug   
“Shake-flask S-pH profiles” 
 effect of impurities, especially those which are ionizable   
“Not contemplated” 
 compound decomposition at the extremes of pH or over long saturation times   
“HPLC measurements provide an idea of decomposition, so we know that additional processes occur at that pH values.”  
 sensitivity of analytical methods (which do you use?) to determine very low drug concentration   
“HPLC”  
 
Q&A Blog 
Q: Firstly, I remember that someone said at the conference that an ultrasonic bath can be used for stirring/mixing 
during the solubility assay. Is the ultrasonic bath a good option for dissolving compounds over 6 h, or is it better to do 
some stirring in the assays? An ultrasonic bath could be an aggressive way to dissolve compounds, to  shorten 
subsequent stirring time. No problems with wetting should exist. Is it true? 
A1:  My guess is that some would think that sonic stirring might create a system that is supersaturated (if the starting 
material is a salt of the drug). The sedimentation period should help the suspension to go in the direction of 
equilibrium. Wetting could make the sonic agitation problematic. (Not sure.) 
A2:  I do not recommend it. If the compound is poorly wettable, the sonication will drive the solid out to the surface of 
the flask. 
Q: One question is about basics of solubility assay. I have planned that I will add certain amount of compound in vial and 
then add buffer. After this when no precipitate exists, I will add more solid so long that some precipitate will appear. 
But if I use this protocol, then I'm not able to say how much compound I add to the solution. Is it better to perform 
some advance experiments before final experiment to get some information about solubility? Another possibility is 
to use DMSO stock solution of compound, but that creates another problem. If I need to add too much DMSO 
solution, then DMSO concentration in solution will go very high and then may influence solubility. So now I'm a little 
confused and I can't decide which is the better option. Which method do you recommend?  
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A2:  It is advisable to work out a general protocol at the start, which can be suitable for the majority of compounds (given 
non-problematic molecules). Someone new to solubility measurement needs to practice with easy compounds. A 
preliminary experiment is useful: try to dissolve 10 mg solid in 1 mL solvent; if the solid is not fully dissolved, add an 
additional 9 mL of solvent (1 mg/mL). I would avoid adding MeOH or DMSO to the crystals. Rather I suggest to 
increase the stirring time and to change the speed from low to fast and back many times. After the preliminary work, 
the frequent difficulties in the case of poorly soluble compounds (problematic molecules) can be considered.  
Procedures in the refined SSF protocol (Baka et al. JPBA, 2008) may be recommended: 
 - two-fold excess of solid   
 - control the pH after 1 h stirring, re-adjust if necessary 
 - incubation: 6 h stirring + 18 h sedimentation 
 - minimum of 3 replicates 
A1:  In principle, pDISOL-X should be able to suggest how much solid to add, since solubility is first predicted in pDISOL-X 
and information about buffers exists. Most people will not use pDISOL-X, so the guessing game will continue. My 
advice is to keep track of how much solid was added by weighting the vile before and after each addition of solid. 
This is more important in the salt region, since that is where supersaturation is most likely to occur, or where micelles 
and salt compete with one another for the compound. Please keep track of how much compound is added. I don’t 
recommend using DMSO stock. (cf., Chen et al., Combi. Chem. HTS 2002, 5, 575-581). If solubility is a problem and if 
you need to prepare a stock solution, use methanol (or any other suitable volatile solvent). When the solution is 
added to the vial (before buffer is added), you can let the methanol completely evaporate, before adding buffer. But 
stay away from DMSO, if you are interested in measuring true aqueous solubility. 
Q: Other question is about filtration. If I remember correctly, the best filter option is 0.2 or 0.45 μm hydrophilic PVDF 
filter. Is it correct? Is it correct to use filter plate with vacuum manifold for the separation or better is use individual 
filters? I plan to perform experiments in 2 mL vials and then pipetting the solution to the filter plate. Is it good plan? 
A1:  See Kristina’s poster about filters. My own preference is to use disposable filter tips that attach to syringes, 0.2/0.45 
μm-pore hydrophilic PVDF. Draw in the suspension slowly, discard the first 25-50%, and use the remainder for the 
assay. There is a lot more to be said about filtration. 
A2:  Yes, it is better to avoid filtration. If this is not possible, then select the right filter type and use 0.2 or 0.45 μm pore. 
Discarding the first portion of filtrate reduces the error which can be caused by the adsorption to the filter. Never 
filter directly after agitation, keep the sedimentation/resting time allowing the system to reach the equilibrium. For 
very stable colloidal system ultracentrifugation can be a solution for phase separation. 
Q: Next question is about buffer. Is it better to use universal buffer (same compounds as your slides: glycolic acid, acetic 
acid, MES, HEPES and taurine) or Britton-Robinson buffer for the solubility assay? Universal buffer should be better, 
but otherwise Britton-Robinson buffer [comprises fewer components]. Which buffer do you recommend? 
A2:  I think the use of the same buffer in wide pH range (like Britton-Robinson) is an advantage, since all the possible 
effects of the buffer components should be the same. This acetate-phosphate-borate buffer provides enough buffer 
capacity and no interactions have been experienced by us. 
A1:  My own inclination is not to use “off-the-shelf” buffer recipes. Select a buffer for the job. Keep the solution as simple 
as possible, and avoid unintended buffer-drug interactions. Also, keep the ionic strength controlled. Of course, that 
requires some experience. There is a lot more to be said about buffers. 
Q: Last question is about ionic strength. Ionic strength of buffer should be 0.15 M. Is it better use for fixation KCl or 
NaCl? Usually NaCl has been used, but in your book (paragraph: pKa determination) is used KCl. I have already 
noticed that SDS and KCl can't put together to the solution, so I'm little worried that maybe different salts (same 
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concentration) can influence solubility of some compounds. [This is] one more thing which is not yet clear for me. If I 
use buffer with fixed ionic strength, then final ionic strength for solubility assay will be very different for different 
compounds. Can it influence the solubility value? Is it better firstly estimate solubility value and then use this value 
for ionic strength calculation to obtain final ionic strength value near to 0.15 M? Or it is not a problem that for 
different compounds ionic strength will be different?  
A1:  For solubility measurement, NaCl seems to be popular. (We have seen the K+ + SDS precipitation, too.) Ideally, you 
want the final solution to be mimicking the physiological ionic strength, 0.15 M. But, sample and buffer will alter that 
value. A simulation using some program (e.g., pDISOL-X) would be helpful. When studying salts, it is not easy to keep 
the ionic strength at the physiological level, due to the excessive sample added. 
A2:  We do not use extra salt to keep the ionic strength constant. 
Q: Why should wetting be a problem in sonic bath? If compound wet very easily, then it should dissolve quickly, because 
compound will be in contact to water. And when compound is poorly wettable, then sonic should help to wet the 
compound, because then molecules will move more quickly than usual stirring experiment. The idea to use ultrasonic 
bath feels more easily performable than construct some device, where I can mix many samples same time. I think 
that if I could use ultrasonic bath, then I wouldn't need any stirrer in the solution, which will make the system simpler 
and no extra thing will be in solution, which should be good thing. 
A1:  If a compound does not wet very well, it just floats on the vibrating water surface, just like a feather from a duck, 
especially one coated with soot. I think just a single drop of methanol on top of the crystals would cause them to wet 
(and dissolve), before the buffer is added. I think the main concern about sonic bath is that it may lead to (super-
stable) supersaturation effects. Perhaps others have experience with this? 
Q: I agree that [it is] better [to] predict solubility before experiment and at least know something about the compound. I 
will try to perform the experiment as you suggest: first add a certain amount compound, and if needed, then add 
more by weighting. Is it possible to get access to pDISOL-X software and license? I think it is important to use this 
program before experiment, because this will make easier to perform correct solutions quicker. This is certain that I 
will avoid DMSO, because I wish to measure only water solubility, not solubility for mixture (water and DMSO). 
A1:  Heath Scientific (UK) is the distributor in the EU: Steve.Stones@heathscientific.com. A 30-day FREE trial is available.  
Q:  I forgot that I have this poster printout. I analyzed her data and I found that maybe it is better not filter at all, 
because sedimentation will give usually higher solubility value than filtration. Is it reasonable to do this? I think 
filtration will be only necessary for compounds which have problems with sedimentation. 
A1:  It depends on the type of compound. Some compounds convert to an oil after the crystals are added to water. Most 
oils don’t sediment very well. Some surface-active compounds form colloid suspensions, which can be lyophilic (e.g., 
gelatin, ranitidine, guanosine), lyophobic (e.g., some nanoparticles), or associated (e.g., “LLPS” – liquid-liquid phase 
separated, like some phenothiazines – cf., Lynne Taylor’s work at Purdue University) where ultracentrifugation is 
recommended for separation.  In such cases, it may be useful to filter carefully first, and then ultracentrifuge.  
Q:  About buffer: is it correct to use different buffer system at different pHs? Or it is better to use the same composition 
buffer for the different pH values, because then all effects and interactions between compound and buffer 
components should be same. I agree that ionic strength should be controlled and if I'm not wrong then every pH 
should be same ionic strength. It means that best buffer should be such which has constant ionic strength over pH-
range or then at different buffers for different pH-s should have same ionic strength. Is it correct? So I will not add 
any extra salt to buffer, since the compound contributions will usually increase ionic strength sufficiently. Although 
for some low soluble compounds it will be important, because then not enough compound will be in solution. I think 
pDISOL-X will be again the solution for this problem. 
Alex Avdeef et al.             ADMET & DMPK 4(2) (2016) 117-178 
178  
A1:  This is a tough but good question. I have done a lot of simulation calculations on a variety of drug substance 
solutions, to see at which pH the buffer capacity is low and in need of external boosting. It is not practical to keep the 
ionic strength exactly constant, and at 0.15 M. The pDISOL-X will correct the equilibrium constants and the pH scale 
at individual points to a “reference” ionic strength, e.g., 0.15 M. The higher the actual ionic strength is above 
physiological, the more tenuous are the Stokes-Robinson-Debye-Huckel corrections for activity coefficient changes. 
About buffers: why do we need to use them at all? Two part answer: (a) In very poorly buffered solution, the tiniest 
addition of titrant to adjust pH causes huge changes in pH (e.g., try getting lots of points in the pH 3 – 9 region in the 
titration of carbonate-free distilled water with 0.5 M NaOH! – not so easy). Also, if the ionic strength is very low in 
the poorly buffered solution, then the pH electrode experiences “junction potential” shifts, leading to uncertainty in 
pH measurement. The addition of buffer in that steep slope region allows controlled additions of pH modifier (i.e., 
“titrant”).  How much buffer? – no more than enough to do the job. That depends on the quality and resolution of 
the liquid dispensing devise. If I recall correctly, the pION dispensers can added 30 nL minimum volumes. My guess is 
that in most cases, 5 – 10 mM buffer is enough. Don’t forget, the drug itself can serve as a buffer. (b) if the solution is 
not adequately buffered, then reading of pH becomes uncertain, and also, trace protogenic impurities can be 
problematic (like ambient CO2: it can cause big pH shifts, leading to uncertainty in the solubility reading for low-
soluble bases with pKa > 8). You don’t need any extra buffering for pH<2 or pH>11; water does a good job there. To 
sum up: use “just enough” buffer only in the regions of pH where buffering is needed.  Of course, that all depends on 
the compound studied.  When the contributions from the buffer(s) added are assessed, if the ionic strength is 
significantly less than 0.15 M, then I would added some extra NaCl to reach 0.15 M total ionic strength. Many people 
would be surprised how much time I spend planning a measurement for a new drug substance. I am not in favor of 
“canned formula” use of buffers. Some labs are fond of using the McIlvaine buffer, which has high citrate and 
phosphate concentrations. It just makes the data analysis that much more complicated. “Theory guides, experiment 
decides,” or “First think, then measure.”  - etc., etc. As a final thought, try to avoid buffers that have high UV 
absorption, if you are doing UV-Vis or HPLC analysis. Some buffers (like phosphate) gum up LC-MS-MS systems. 
Q:  What criteria did you use in order to make the conclusions at the end of the filter-selection poster? My working 
hypothesis is that if the value of solubility is unexpectedly low, then filter adsorption of the sample may have been a 
problem. This is a common assumption.  
A2:  Yes, this hypothesis is correct. Those conclusions were rather suggestions. It is better to avoid the filtration, but if not 
possible, we have to select the right filter (hydrophobic for ionized polar species and hydrophilic for unionized 
lipophilic species); with discarding the first few portions of filtration, etc. 
A1:  However, can there be a case when high solubility is not a good result? If the solubility assay produced some (not all) 
very tiny particles and if some were able to pass through the filter pores, then the measured solubility would be 
unexpectedly high. 
A2:  It may happen. We think that when we filter a high concentration solution the filter can be saturated more quickly 
and the error caused by the adsorption is relative less. 
A1:  Did you have any suggestions about how fast (or slow) to push the syringe plunger through the filter disks?  
A2:  Good question. We filtered 300 μL and 600 μL portions, generally quite slowly.  
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